Skip to content
RNAWiki
Checking…
All public datasets

Public dataset

Recorded source agreement and disagreement

Show whether sources print one normalized reading, have incompatible units, lack structured comparison context, or contain a context-matched numeric difference.

What this does not mean: agree can mean only that sources print the same normalized reading; it is not clinical-context equivalence, independent replication, or proof. differ requires matching structured context and disjoint comparable values. not_comparable and insufficient_context are not disagreement.
Public rows
1,681
Generated
Schema version
source-consensus/2

Coverage

What this run contains

Compared medicine fields
1,681
Agree
1,282
Differ
0
Not comparable
12
Insufficient context
387
Fields represented
5
bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution

Method

How the rows were made

  1. Deterministic rules normalize recorded pharmacokinetic readings and compare only like-for-like values.
  2. One normalized printed reading may be agree even when clinical context was not extracted; this reports printed-reading agreement only.
  3. Distinct readings may differ only when their units and denominators are comparable and one matching, non-placeholder population/formulation context was structurally extracted. Otherwise they are insufficient_context.
  4. not_comparable preserves incompatible units or denominators instead of guessing. insufficient_context preserves missing or non-matching structured context instead of manufacturing agreement or disagreement.
  5. The agreement rate describes the distribution of recorded source readings; it is not a probability that a value is true.
  6. Every distinct printed reading retains its unit, population context, source count, and complete source records. The API paginates field rows, never child readings or sources.
  7. documentsExamined is every matching single-substance archive document inspected for that medicine. The generator has no document, reading, or source ceiling, so there is no hidden available-versus-retained remainder.

Limits

Read these before using a row

  • Current label parsing does not structurally extract population or formulation context. Distinct otherwise-comparable readings are therefore insufficient_context, never differ; agree may mean printed-reading agreement only. Source records are complete but are not independent-experiment counts.
  • The current deterministic parser does not structurally extract population or formulation context from these sentences. It records that context as unknown and cannot publish distinct same-unit readings as differ.
  • Neither reading is marked wrong. Population, formulation, route, and other unextracted context may explain the printed difference.
  • Only the recorded fields and source documents in this snapshot are compared.
  • A source count is the number of retained source records in the row, not a count of independent experiments.

Provenance

Source examples

abacavir · bioavailability · agree

15 documents examined; 83% (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:5676d391-f9a4-44be-9604-954b3d8d0e2b (opens source in a new tab)
The geometric mean absolute bioavailability of the tablet was 83%.

alemtuzumab · volumeOfDistribution · not_comparable

2 documents examined; 0.18 L/kg (Unknown: population and formulation context were not structurally extracted from this source sentence.); 14.1 L (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:4f5f7255-7abc-4328-bd1a-ceaf139ef3e0 (opens source in a new tab)
Distribution After the last 30 mg dose, the mean volume of distribution at steady-state was 0.18 L/kg (range 0.1 to 0.4 L/kg).

abiraterone · halfLife · insufficient_context

31 documents examined; 12 ± 5 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.); 18 hours (Unknown: population and formulation context were not structurally extracted from this source sentence.)

FDA_LABEL:c9eb9b46-f847-40a8-802c-a51b40406d5a (opens source in a new tab)
Elimination In patients with metastatic CRPC, the mean terminal half-life of abiraterone in plasma (mean ± SD) is 12 ± 5 hours.

Artifact used for this view: data/source-consensus.ndjson. The reader resolves the current run first and uses the checked-in compatibility run only when a current artifact is absent.

Schema

Fields in the public projection

FieldTypeMeaning
medicineSlugstringStable RNAWiki medicine route key.
fieldstringRecorded pharmacokinetic field being compared.
comparisonStatestringagree (printed-reading agreement), differ (context-matched comparable disjoint values), not_comparable (unit/denominator mismatch), or insufficient_context. Every state remains declared even when its current count is zero.
comparisonReasonsstring[]Deterministic codes explaining the state.
documentsExaminednumberRecorded source documents considered for the field.
sourceCountnumberRecorded source readings represented.
agreementRatenumberShare represented by the leading normalized printed-reading group; not a confidence score or clinical agreement probability.
readingsconsensus-reading[]Complete, untruncated reading groups. Each keeps the printed display, numeric value when parsed, unit, population context, source count, and every source identity, version/effective date or explicit absence, retrieval date, locator, safe link, and excerpt.

Reader

Search and filter the rows

Case-insensitive text search over the public fields named for this dataset.

Exact comparability state.

Exact recorded field key.

Clear

Showing 661–670 of 1,681 matching rows. Filters and search terms remain attached when you move between pages or open the API view.

  1. Projected row 661

    Medicine slug
    furosemide
    Compared field
    bioavailability
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    151
    Source count
    9
    Agreement rate
    0.777778
    Recorded readings

    1. 64%

      Numeric value
      64
      Unit
      %
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75d68f19-424c-109e-e053-2991aa0ac857 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        In fasted normal men, the mean bioavailability of furosemide from tablets and oral solution is 64% and 60%, respectively, of that from an intravenous injection of the drug.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c9b4d8f-0770-482d-a9e6-9c616a440b1a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        In fasted normal men, the mean bioavailability of furosemide from LASIX Tablets and LASIX Oral Solution is 64% and 60%, respectively, of that from an intravenous injection of the drug.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b9af6a4-e1da-eb95-e053-2991aa0a031d (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        In fasted normal men, the mean bioavailability of furosemide from tablets and oral solution is 64% and 60%, respectively, of that from an intravenous injection of the drug.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5db2be1-088f-1110-e053-2a95a90acac8 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        In fasted normal men, the mean bioavailability of furosemide from tablets and oral solution is 64% and 60%, respectively, of that from an intravenous injection of the drug.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75d5611a-f9e0-1841-e053-2991aa0af415 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        In fasted normal men, the mean bioavailability of furosemide from tablets and oral solution is 64% and 60%, respectively, of that from an intravenous injection of the drug.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5db4434-0b47-038c-e053-2995a90ad7fe (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        In fasted normal men, the mean bioavailability of furosemide from tablets and oral solution is 64% and 60%, respectively, of that from an intravenous injection of the drug.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c5d9b063-e3fe-ec2f-e053-2995a90ab3f2 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        In fasted normal men, the mean bioavailability of furosemide from tablets and oral solution is 64% and 60%, respectively, of that from an intravenous injection of the drug.

    2. 107.3%

      Numeric value
      107.3
      Unit
      %
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eac958dd-8d43-e44e-e053-2995a90a4d5e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        r was up to 8 hours after initiation of dosing. 12.3 Pharmacokinetics Absorption In healthy adults, subcutaneous injection of FUROSCIX (80 mg furosemide injection via the ReadyFlow), the bioavailability was 107.3% (90% CI: 103.9, 110.8) relative to 80 mg intravenous furosemide (two 40‑mg bolus doses separated by 120 minutes) with a median (min-max) T max of 0.75 (0.5-1.5) hours.

    3. 112%

      Numeric value
      112
      Unit
      %
      Source records
      1

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 1 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb27654f-c7a1-4796-ab08-60a5fa16f5c0 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        nd Class III heart failure, subcutaneous infusion of Lasix ONYU (30 mg furosemide over the first hour followed by 12.5 mg per hour for the subsequent 4 hours, 80 mg furosemide total), the bioavailability was 112% (90% CI: 104, 120%), with a median Tmax of 5 hours relative to 80 mg intravenous furosemide (single 80 mg bolus).

  2. Projected row 662

    Medicine slug
    furosemide
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    151
    Source count
    148
    Agreement rate
    1
    Recorded readings

    1. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      148

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 148 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4b3e2e13-a657-4da5-b536-8ae0a26812e0 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15ae6f44-88dd-4455-b1f7-4718c91e7b66 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a2235e8-d488-2d43-e053-2991aa0aa485 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ad12e70-3c2e-44af-bb6b-5762d181c76b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43be0231-0d88-4a21-b2ab-793155cbddb2 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:813c8e9b-61bc-27c4-e053-2a91aa0a9f45 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d76bd85a-8e57-477e-9607-c9435f1e26fb (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d7eb469-2371-4abb-8f49-be1596f10f27 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f3248cd-d62f-49ca-8788-f059e8facd91 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3745be12-ea1d-f450-e063-6294a90a148c (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd45c963-a413-e9a1-e053-2a95a90a1438 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bd1b15e-354e-051f-e063-6294a90a3f3b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e0bac29-5a8b-4d4e-93b3-2e21eb3b0650 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39fd32f2-6bb7-4a65-d298-e48d26bc80c7 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6d9caaab-d874-4cf1-b9fe-408452a18998 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01a5f094-b473-4e46-9e61-69d5ec6dd766 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60cf5e60-9a7a-42c2-95b5-016f7a68ffc4 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d07ff11c-c1ab-41e6-a455-f2b89340106e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0a105e0b-b5cc-d929-e063-6294a90a80af (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6cbf3834-0433-4dc0-e053-2a91aa0a8f8a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7316929d-413a-e78f-e053-2a91aa0a417e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0dd28e18-2e15-45eb-9a61-a9de7bd7d64e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3747bbcd-783d-4baa-bb5b-b6827bf390e3 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6101b9b4-f3ef-438e-a857-b4ea55ffc679 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7842eeab-decf-47e7-9134-0add90549a3d (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d75ba8bd-9494-4306-8443-9c1a90992dd5 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37457273-38a1-f938-e063-6294a90a50ab (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cad102d7-0197-4cff-bb80-9f0b5bcb599b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7181e528-c862-4dd7-8446-9011e4c7312a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9ec7808e-9201-4b8c-9790-d329320dc6c4 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fc3194a3-7e75-4551-8334-4a5cc22d9f8b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:809d9734-12dd-3b1f-e053-2a91aa0aadee (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bbf03f9a-ae33-8da1-e053-2a95a90a3bdb (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6c2ee3a4-afea-4e1f-84e6-def0221ad437 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5e94bf3-bb18-4c81-98af-8c1cb7e00496 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75d68f19-424c-109e-e053-2991aa0ac857 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:114f4f4f-536a-4658-8fd0-2dd8c029b19a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0aab9759-ee48-d1d3-e063-6394a90a2741 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0acd293b-ecab-4879-a8e7-cd1b76148f2a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5b9f12e-d1e9-42de-90f2-c9ba33a86457 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d0db0f7-bf4f-4b0b-9359-2a838626e04b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6194face-c26c-46ed-bde7-1e29bfeabd88 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f6529fb-1173-ada3-e063-6294a90a76cb (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f2b920b2-f8b3-1e6e-e053-2a95a90ae153 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c9b4d8f-0770-482d-a9e6-9c616a440b1a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:916de29e-228c-4dfc-bcee-ad9a641316bd (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dba00759-87b4-4ecf-998e-ba03ed3d2f1a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:644704c0-e6a5-4804-bfa6-795c8f83aa7a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f3173c0d-2b62-7c7b-e053-2995a90ada05 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12137a90-fb35-45d7-8984-0b04793d3e34 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ba730ab-90d4-478a-80b3-1ea3edb03e4d (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b9af6a4-e1da-eb95-e053-2991aa0a031d (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a746634-379b-4847-a965-7607d2a71bed (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ddfc41a9-37d4-49c1-bbf3-969a98cd649c (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2e3c748-28ce-4c50-a182-721912919840 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f56d6f6-a5ea-4171-9e24-d2fdb11a65f8 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aaced7a8-c3d7-4d66-8c07-aa407b8b3f35 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:71b48f4d-9936-448c-9e3a-33f1182e1039 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2a5bcf50-6d63-463a-915e-a72ea2e5f131 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3d312ab0-589c-427b-84da-18887244bfc9 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a23fc1e0-2d16-43a8-a34e-f6505dcd6316 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:341e29d9-a6f1-4c77-ae44-9b2c423ea6b4 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54a33042-a163-4f93-96cc-fbd93030e014 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48d8f490-e9d1-4c95-ab2f-414d3f4a9df4 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e20257f6-7cfe-43fa-a672-cc1cb312b83a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9853417-0442-4f53-9543-e0749bc3c80d (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6be1addd-a811-47fc-8650-6870d661c234 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54dd664a-c7ec-27f3-e063-6294a90aff9f (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:571a52ed-5258-46d5-a0d2-9a984cf73895 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eac958dd-8d43-e44e-e053-2995a90a4d5e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2590ebb6-ce2a-4e23-9244-e54e3010d488 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8ebd2f10-acfc-48a4-a5db-f20377bda9ce (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:600ca175-be2b-4c43-b119-133ae21a5601 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:020bc039-9e99-4895-96f8-0c6a556d3e67 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:595ddaf2-c2cb-44a4-a46c-53bcfe6bd752 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8a064cc-c741-8b80-e053-2a95a90a364c (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d63c1277-dd7e-4d21-9e80-68143f55e2dc (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d2733ac-6fa6-44d1-96d4-f1a698045ad2 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b028a3c-102a-40f1-820e-b187ff1e1803 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6947af02-f50b-7f9c-e053-2a91aa0a45cd (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b3d986c-eecc-adbe-e063-6294a90a0fb2 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52e75604-5766-40e8-a13a-8c449e06ebda (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c24489c3-65e0-44e3-a50a-8bb0672e8821 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8407b0e-7838-4ab6-b9dd-1f7ecf1e0a17 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c81d313c-65a3-4fb5-b6cd-b1c1ec7dca03 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fbf7f3d-7566-44d5-9507-c4460238fc91 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:42478c55-9056-487a-89a9-d36904beea12 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75d5611a-f9e0-1841-e053-2991aa0af415 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53e58232-f7f9-c09b-e063-6394a90a5bc4 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e493331-dddd-496e-abf8-61747fb67aba (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08a44bdd-028d-41af-9d4e-70971b0bcc4e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c71371a7-75c5-45b8-b762-8d782d4c71bc (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c90bcb14-eb8d-4753-b339-3469c664ecd2 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:809b4f68-4fca-c201-e053-2a91aa0ac18e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:92f3ab5d-361c-4e12-bb50-fd4a9f195a8f (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ea4ead7c-c798-2d85-e053-2a95a90ab0b0 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52f0c9d5-396f-4033-abe8-145eec3e6983 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a2e46e16-4adf-4599-b69d-a6f6f891ba75 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25c0aded-ffcd-4145-a48c-76c5fb220f61 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ede9846b-b4c5-4be2-9188-fd65e66cd893 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eed4bbf-7d0e-e852-e063-6394a90a85c2 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43053bf7-9050-dba8-e063-6294a90a7174 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38550de1-f099-0cdf-e063-6294a90a9e26 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cc2c2d1-2fa4-f6b6-e063-6294a90a290e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:febeaf8c-0f4b-cc40-e053-6394a90a873e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58d2a38d-75f8-dcb9-e063-6294a90a10d7 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58cc1e38-6000-1489-e063-6394a90a5978 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:462e8917-cbe0-f4f9-e063-6394a90ab4ff (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ab1a7e16-f746-41af-8faf-b69d3ffd62ba (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f124d7d-a19d-4de6-8ea4-719a42eb520b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2cc89e5-6619-4113-ad31-48076652c856 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6820724c-1ca5-451c-9d2b-2d38e60036f5 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:440aaaed-47df-4bb5-8b41-2c8056893679 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c794c95a-654e-48fe-9596-201fc122ff75 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:15e4c3a3-7d64-471e-bfdf-6156731e24aa (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aadaca7-3661-4bfe-87f8-6368e4ab6536 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ecaa5af-d186-4380-b105-e7e528f75cc7 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:83662449-f2b1-48a3-9021-13037e64e6ea (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4c532be-1f3f-60d3-e053-2995a90a98be (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b9117d5-0dd9-4577-a1fd-bb0aaf7e68ec (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c342198-7162-4cc5-bda1-bc4054a4292b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a0fb397-63ae-4fce-bddf-16a91b1b7a2f (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6864b3f6-c5ad-4588-ad04-5260258c6d8c (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6221cce-e586-4002-bd14-6ec22eb14e2e (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b5c6fcf4-fd37-4fee-8dac-1a3273d95ffe (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:307c3b89-f37f-45ee-8ec7-d402008cf2fa (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:33ec71e2-8fbd-0703-e063-6294a90a62e1 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a504ee4b-3995-45f2-898c-91116dd81d19 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:421aa6d5-623b-4dc2-abd5-bb9e7765bf37 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      130. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ac64c926-88e9-453a-884c-72ec6a1c746a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      131. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb27654f-c7a1-4796-ab08-60a5fa16f5c0 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        ) 2010 ± 391 13000 ± 2510 3.7 ± 0.7 13100 ± 2550 Furosemide administered as single 80 mg bolus dose intravenously 13800 ± 4100 11900 ± 3380 3.7 ± 1.3 12000 ± 3400 The terminal half-life of furosemide is approximately 2 hours.
      132. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13ba97a7-598a-76a4-e063-6294a90a45c5 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      133. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:adda78ee-0cf5-4613-a748-5d6571afe354 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      134. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8c27f1c-dc81-44b1-8663-a7d663bad89f (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      135. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ed0dd9-2fa8-269a-e063-6294a90a607c (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      136. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7cdcd001-ab4b-4210-a455-2e17a7bc4972 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      137. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6f64972-714c-4ee9-8a5e-9ffcab41a73b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      138. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e9be5c3b-4b18-7ad2-e053-2995a90a4a8b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      139. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1d99e151-75ba-6a75-e063-6294a90a4360 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      140. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20eecc36-dfb7-0060-e063-6394a90a9d0b (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      141. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25171259-dcf1-4984-9581-cd69dee8dffb (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      142. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce84359c-2f76-421a-9b2b-79b1c2be2f20 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      143. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:73e5c8f3-32f8-114c-e053-2a91aa0ab500 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      144. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3fd02fb5-98a0-4eda-a0ec-41faabe04706 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      145. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:53c3f50f-57c6-441b-afea-ec43d7943d1a (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      146. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85375079-a9f1-42d4-8e15-c1d31395b29d (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.
      147. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4227fab8-a64a-1c9e-e063-6294a90a0682 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        Elimination The terminal half-life of furosemide is approximately 2 hours.
      148. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f547f7c-0322-465c-9764-43f955d98ab2 (opens source in a new tab)

        Furosemide label

        Version not recorded · Effective date not recorded

        The terminal half-life of furosemide is approximately 2 hours.

  3. Projected row 663

    Medicine slug
    gabapentin
    Compared field
    bioavailability
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    411
    Source count
    399
    Agreement rate
    1
    Recorded readings

    1. 60%

      Numeric value
      60
      Unit
      %
      Source records
      399

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 399 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b6db5ce9-bd4b-420d-88a7-df9d46144c81 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5073abda-321f-29d1-e063-6394a90a59ac (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c898711b-9a65-1816-e053-2995a90a855e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0eb27e64-1488-4083-82c7-cebb8c0605de (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77d1d90d-e124-4db7-b811-754d535e579c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a900bafb-8f49-4a01-ba7f-4fb228ec0253 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75418d32-6504-4cb4-b3a9-afa0eaf19b8d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b76955c-52a4-4026-b286-3da1112fe989 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fb79774-c2d4-47ba-9a16-eb367d0fdcff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba2a8352-5776-4edb-914e-ce1d18ccda32 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbc05ceb-2e69-3c37-e053-6394a90ac4f4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c89a68b6-6dc0-4624-e053-2a95a90a687e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b37b1dcc-c7e9-8845-e053-2995a90a089e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5b47f89-ed35-31de-e053-2a95a90a5554 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e90d2e3d-ec86-7d1d-e053-2995a90a9167 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c65253d-ca49-70eb-e063-6394a90a3cd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7fcce531-bf7c-43b6-bea9-8f0602842c53 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:969cccfc-e56a-49da-9d36-47c0c3fad7f8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2278ce1b-1c19-4ad2-89c6-4530f7b78ea7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5134369d-c7f6-4569-a425-d50e5a5d694f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:344d67fa-092e-4e71-b96a-25c71bfa6bb1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:781b0d62-a760-4371-8908-1f61329928a6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aaf3d6e-c6d5-89f5-e063-6394a90a9b77 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f350a4b-f294-4b98-b69f-3cc789e930ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b88b0cbc-c883-4d17-8f46-0e5bddc57835 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09736975-2493-4dbc-bbe0-cc56a1fec53f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ab9c18b-9568-4dcb-90b0-252aef8f8dc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc83432-8fce-6d2a-e053-2a95a90ae73f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38119f2e-33b3-4c3c-99b7-9335d8d280d4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7a29b99-ce23-950e-e053-2995a90a1934 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9f0cceb-b24e-4526-b873-fedd877d6bc6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e633cd0-5ee8-4a05-bcfc-0a80209bf27f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6beed8eb-446c-4575-8dc8-b798623d92c7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55292235-bf8f-46d0-e063-6294a90a91a5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81243958-cc5a-4ec0-a64d-71682f949d5f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:360d953b-4313-45ae-b933-296547d4577d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ac0622c-440a-49a0-974f-726e6ac72a0e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48037fc4-1aab-4ae8-aede-7c55b494877a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1006139-7dfc-4d87-a5a9-aeb380c32d24 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ddc7d92-9076-41cf-97ed-d9f9edc80298 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c585b71-5cfc-18d6-e063-6294a90a3dcf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81774da8-cb1d-4c7d-8550-35396850d5ff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74474aa4-4859-42d2-92d8-f23f18b34e04 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da8438e1-755b-4195-baa7-464f3d9ee5bd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bbfdedd7-2baf-4bc6-be59-548a5cf21752 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c8dca11-78ab-45c1-8bb2-89a41ea5dfa9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a072d5d2-8c75-59cc-e053-2a95a90ac0cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff28c5f1-da56-4072-a6fa-d689d4a6761b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40bb60c0-a2f3-4e7f-b13c-028c906c4852 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fc8e8b2-5d0e-4c72-9a46-6d312c3efac7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1749d731-bc8c-4374-b2a9-7c809c457f56 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b67b7865-df64-429a-9550-5333b9c713ea (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b2f38ef-0a0c-45cc-88ca-cc086bf80641 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39149f0e-30ed-4671-8be7-2a484f65d63b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79cd9dea-e7d0-44db-afba-964cb99f32b6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:645824d0-eb3d-442b-806d-36a70796cb8e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e7f602a-2c5f-4651-a228-5fc5bf249205 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c859e666-d510-426b-e053-2995a90a9a3c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f781d400-7304-5d3e-e053-6294a90ac572 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87b9171b-7d00-40fa-87ff-a717740efe8a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23eb133e-2f74-4219-9892-0a8e770ec032 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d3fc163-25f0-2c61-e053-2991aa0a76e9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c3b232a-3e9f-4249-9e5a-295482ee288a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:707ed63a-67ca-4a62-9cbe-cdeb5c4ab506 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47a22de2-ec66-45be-8648-89ed3ab6e67e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1373587e-807a-462a-bff6-8a7113ce9f0a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f982b95-4e84-4e0c-a543-747bc3dd7531 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e28ad3d-2d34-a5d0-e063-6294a90adb9e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d22ed424-f365-44ca-8ef9-a08255a90ae8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35da078b-0da0-4757-a6c4-a9144c37e8e1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07aa1bcc-df05-44fa-92d4-63894e0e6cd6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c681c804-c6f3-d63b-e053-2995a90a6b8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b175f8d-7667-4bfe-8bb5-fd7441eed456 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08880902-bd44-41b6-866b-2cbad4c3f2b1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:691205ba-fa65-4bc9-ba20-7d361382cff9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58474aa7-7c6a-3a94-e063-6394a90a870b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7652adc6-1aad-4422-b85c-0c6b11c23b73 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97e47698-97c9-4eb5-a108-5850c2aa2818 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8de89818-805a-4a20-a9b1-48cf443b6315 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c78f528f-9192-4037-bfb9-ff5718ed26c5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7538e255-95df-4991-aae0-a90d709f1e95 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bae5032-f634-4d1e-b672-8a7e2bd6a5fa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1200 mg, 2400 mg, 3600 mg, and 4800 mg/day given in 3 divided doses, respectively.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa3ab216-372a-4a72-bfd1-88a1ffa31ba3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9c99dfa-f54d-9207-e053-2995a90ad43b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:506bf880-9564-404c-951a-703797ffdad8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c33c4d83-cc13-4104-9e24-d4cd40b17b70 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8a30eb7-3fc5-456a-bdae-3f4095bf2c2b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07871ab8-254b-e3c2-e063-6294a90a29ab (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cdbb381-88a2-5c5a-e063-6294a90a3e1e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64a65366-8577-48f2-9f8e-0332f126d3c1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7c1fd34-d615-43a2-8989-898fe11f90df (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f2ba3d6-6086-eaf2-e063-6294a90a7642 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of Gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b74a427c-9cc1-4b15-9ed2-cc891741fe67 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b26fd0c6-6aab-4957-8a32-cc7adb9b5fc9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ead7343-ab25-41b5-af4f-f903470e1dd9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c979f80b-d4b1-40f7-b878-b216db5f325d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67330eef-c976-4862-b1ae-20f30f43df76 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:266ef369-0a56-f225-e063-6294a90a495e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ddc1342-5c83-f562-e063-6294a90a29ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce0f0d7f-da6d-47da-a4ed-fb8f72902412 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eeb19a5a-b31d-4df8-9546-0b2b5eb5db07 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd5c9279-a1e3-2a59-e053-2a95a90a33a2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5eff7ad8-0d31-4372-82a2-ac9f549d8796 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c49d34d-bb47-406b-8f2d-b4834b2ee9d0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07f07d15-ee91-8c2a-e063-6394a90a4624 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c85ae572-9893-629e-e053-2995a90a23fc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14b1840d-a2db-4eec-bc25-029e35b042e4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:172776c0-909e-49ce-bfe1-cf154a9458ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:100ff86c-56a8-4770-9db3-b9bc6b1bd2f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56378630-e7a7-4981-8212-8ea703a433d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54c09aa5-6724-480a-a115-c88484e39e93 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9ead7825-d11b-4e00-8533-328d097b8f83 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cb1ad6d-d389-4564-e063-6394a90a3644 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:743faa18-5e7c-4fcc-9781-4157450d90c4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc80b8b-da39-6fb9-e053-2a95a90a2d8e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1278512b-1493-db65-e063-6394a90ab161 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d544944-ea95-42e1-8c65-9e442437f0ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b73e9db-eddb-49ba-9778-01d39ece4d16 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a2aa696-7dac-4d03-916a-374b61a255b5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:185f264e-db32-41cd-b90d-519717b97850 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2dad630a-09d8-4f40-bdad-24e877a9ee38 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef37f2a0-3b83-4f71-91c0-6435161b483c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db57e37f-0a78-4c14-8768-a28bbf9fa0da (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffe5321d-3405-46d5-a75f-c51e8f8d87b1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:330ddc5d-c67c-33dc-e054-00144ff88e88 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:137b2b9a-9d42-48d0-913f-5dc146fb689a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4470a567-93a6-a293-e063-6394a90affc1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of Gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41d1ead3-046e-4abf-ae0a-cb126a1f5848 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      130. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:912d8697-b466-48dc-88d3-d2ba90e76644 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      131. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de990f96-96bc-406d-e053-2995a90abebb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      132. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13640281-26b4-402e-8f69-7c81cd6e0376 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      133. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4f21e97-5e55-44c9-9b31-5f79ac2eb512 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      134. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8604417-9d43-4d27-a7ce-d4120ff201f4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      135. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1eda6cc-d9b2-4df4-a09b-20eebded760f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      136. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:235a6954-318a-9e3a-e063-6394a90a0e21 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      137. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:021329d0-7d32-4fd8-81bf-a8b0d8b49e43 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      138. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd7adad2-e2f5-4b43-90a4-522bce0be5b3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      139. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:429a1bb5-babf-4f36-8264-46d71164f1c0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      140. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57383d2a-d2c7-bbdc-e063-6294a90ada98 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      141. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fce0c123-29d7-42bf-8c8d-8be1772e2d99 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      142. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:507bf6d0-e7a2-413d-9848-cd2445a1411d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      143. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5954a330-c225-00bd-e063-6294a90a7581 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      144. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d06380d0-c894-427e-b13e-5a8f9eb86a34 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      145. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:596eb696-7696-202e-e063-6394a90a2844 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      146. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6ff265b-569b-4f5c-8fdb-00b7ad4aac7c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      147. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6ecf5114-2ddc-4025-a36d-1884702dc22a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      148. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:081fd1de-acaa-4685-a053-4959d77b17e9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      149. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bff3beea-1f05-4e84-bcd2-d05782acddae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      150. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbeccab7-08aa-4da3-868f-b47a1f3d41ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      151. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f70c496-b58c-30f5-e054-00144ff8d46c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      152. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:561f53d5-5301-42b3-b372-f3d49d642a2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      153. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:92c4d589-533b-4fe4-833f-dd68cc1f7e66 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1200 mg, 2400 mg, 3600 mg, and 4800 mg/day given in 3 divided doses, respectively.
      154. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d77dae0-df76-4b7b-9690-713e9a60e3cd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      155. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed22b78e-93ff-4cb5-9c9c-2afe9b60dd2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      156. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7cb37f9-e1df-4e2a-bde5-9bfa0e040d7a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      157. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f38098ec-dd1a-405a-bbfb-bad62e4e7fa5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      158. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7a943ec-9a13-45ba-9bc5-18162b86b921 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      159. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbedccfb-0e27-4119-93b9-241c039e045a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      160. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:657349fb-41a9-4814-b4ac-4c5afbdde947 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      161. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:477691f5-0591-4544-840a-ac590e1f25a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      162. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b33c18ea-554d-3cfb-e053-2a95a90a2dd1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      163. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec1a01fe-5531-21df-e053-2a95a90a0561 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      164. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95757436-2093-41cf-a9a9-ef2f28ac096f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      165. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472bb279-bb4e-4246-b2a3-172483ba356b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      166. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:310ce005-5a24-489a-b23c-d42ab6a3bfed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      167. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa246838-609c-4254-a8ec-d6f463a17960 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      168. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9d78138-e1e9-4107-9099-4910cb1422d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      169. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:618c948d-deee-44e2-98f0-e5232171dd50 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      170. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:685553b0-384e-400b-a8ae-612ceece8261 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      171. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc1998a7-7004-4688-8b5b-525041851d1d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      172. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e4eca9c-6a2c-4ede-a252-1a27094bf594 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      173. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bfee67dc-d2b1-4a00-92d9-a42be3189c74 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      174. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cc6615b-5447-9c0e-e063-6394a90a2883 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      175. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cb26d6e-7963-4fe5-903e-ab5180545066 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      176. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:798575b9-ddfa-4915-9574-626abbaf025f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      177. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ecc64b-f019-9fcb-e063-6294a90a00af (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      178. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5969871e-6c71-4c37-9d63-370718ccc80c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      179. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df9c7c84-a8d9-4da8-babe-c55c9420d4e6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      180. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff7de45-148b-4e96-88fd-6052bf75b5f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      181. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1af098ad-28b5-463f-8efa-24d70a77d64c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      182. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86b30e64-fe56-42b3-a0f8-d9ef5d4b8c49 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      183. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ddb3a54f-5224-4024-8804-b2a2f01d885e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      184. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97935fd9-1d4a-43b6-a5d9-de994591187b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      185. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47cd25f6-e123-9aaf-e063-6394a90aeedd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      186. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26aac429-a5cd-33cc-e063-6394a90aecc0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      187. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2da7d96-73ad-4f44-8784-160a384a0961 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      188. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f396ec70-826d-45c6-a27c-343c2fac878c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      189. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:167d8b87-506c-4293-9579-563feaa71583 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      190. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca8177ed-1f0d-436e-a5ac-f58b8f7cbb25 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      191. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:772d9e7a-3811-455a-99e6-f2a3d0769b9b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      192. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed3a0d48-2e98-44ee-8743-880d1221a480 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      193. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b404ab9-8a7e-49d4-920f-487875d14e45 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      194. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77754734-4125-42b1-97c8-458bcab2bcf1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      195. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45039bba-7a96-450c-95be-83a3aa4fcbd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      196. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b4395f2-9440-4b67-97cc-5d16f3bdd05e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      197. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ef99c3d-866a-438b-a340-8beba8d4c457 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      198. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7790d906-af26-4e60-bc6f-e906ec03cc24 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900; 1,200; 2,400; 3,600; and 4,800 mg/day given in 3 divided doses, respectively.
      199. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9efd0261-9fc9-4dc9-8cf3-9110157ddfc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      200. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c79d94ec-117d-4fb6-845d-1954e3472bb0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      201. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78088f6a-06a3-422f-b336-4a57a24adc16 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      202. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2d9bd8c-3bb9-4945-8e61-7d2703d9008c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      203. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1fd95278-842f-4bf9-abd5-4d9aa858d36d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      204. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41ce952c-6c16-4b5d-adf7-9ea114e63eb3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      205. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30a2ed14-dcda-f972-e063-6294a90a417c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      206. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11645bd6-7cfe-49b2-9292-2e4b0dbb84ae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      207. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d3f27bf-3486-40fa-a4d3-5f0b2c6c0151 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      208. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eaf5e41e-8ed3-404e-84e0-392bebdbc0b7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      209. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:44f2b497-55b2-864f-e063-6294a90ad6d5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      210. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3865a6e3-112c-490c-82ac-35401336b16e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      211. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b86c81d9-9a4a-4847-be18-520e5cc5dc4b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      212. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02304deb-7b4a-452f-9b1a-64ca0aedbcc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of Gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      213. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4aa69d04-6b32-4764-a48b-ef5313dd95d3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      214. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75caca13-1432-4c0d-8d45-f029b0b2d417 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      215. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180b99a5-7d3d-4ee5-a0cc-1ae0ede646ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      216. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:152adf1d-ec0c-4561-bf80-e4c7da158723 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      217. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ea83c18-7107-41f4-8305-62725c1c45c8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      218. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:397fd6d3-317b-4b61-a52b-3a09ca1d88a4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      219. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36f74fdf-0dae-47a0-a7ea-e64ac91cd88f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      220. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a0a75ac-e121-477b-a9d1-d11f588afc9d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      221. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:722de2a9-38b3-4518-b262-ba0d1346d0ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      222. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:896c7782-1137-454b-aaa6-28f42c7413ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      223. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f31172a2-0ae9-49f2-b797-b26fe33f3f64 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      224. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d401e54-d4f5-43ba-b898-dd08fc3c7bfa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      225. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b44a3ab-4d06-205f-e063-6294a90af368 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      226. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a95f18e-0de4-4ce1-9f97-bc2e8a5bac6a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      227. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:500ee820-0378-6fc9-e063-6394a90a109c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      228. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:632cb507-5675-2392-0460-b09c0dd14650 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      229. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25befbfa-5125-4363-8306-f862e81c0a6f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      230. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5c9dd2c-b8ee-1406-e053-2995a90a0287 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      231. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af73fbd8-9731-e6bf-e053-2995a90af65d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      232. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b062f12c-a745-76d4-e053-2a95a90a3a1a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      233. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed219efc-84e3-5bdc-e053-2a95a90a56fc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      234. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fbd601f-df95-4a79-a7d3-c3505e23b913 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      235. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9bf87e4-5499-4dd7-a0c1-16025a718d14 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      236. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88ac51c4-5fa9-4c35-9c63-f26bcb101d4b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      237. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20e48004-d8b6-40fd-929b-b95087b4d85d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      238. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12f0c2ee-9a44-9778-e063-6294a90a3b58 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      239. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47f2a06f-4eac-4dca-aa2a-a36dd4daaea0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      240. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af62bb7e-162e-4e2a-8eb0-d50f66678707 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      241. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5769d849-4f27-4701-97ec-7e3ca07339d7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      242. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afa28969-91c8-83fd-e053-2a95a90a656b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      243. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:faa47fcd-2545-a946-e053-6294a90a05d2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      244. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13b87441-8fe1-40f5-8ffb-00dcd8cc90a6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      245. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:febf610e-e088-4797-e053-6294a90a3eb5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      246. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3133fc78-dd7a-880c-e063-6394a90a89e1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      247. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eeda97d-c3cd-65cd-e063-6394a90aae8b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      248. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e900fc4-a2b3-411f-9ab7-8dcbb97b697b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      249. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e847bcfa-f3de-404a-8a57-d8a414691e6a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      250. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e331641-ec26-4d76-b16b-a9863c767afe (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      251. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1045db4e-4c76-4a0d-bf12-019bd96a8f59 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      252. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:999f3685-2eac-467e-bed2-1d0c36aaf0ed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      253. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17a62334-209d-4dc1-867a-e5780196a2ca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      254. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d445d1d-02d1-4a59-b3b2-9ba5cd924c9a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      255. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f1203f4-2184-4e13-e063-6394a90a4330 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      256. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f93eaa4f-cc1a-10ab-e053-6394a90a5ffc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      257. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2bc65375-77b8-1e50-e063-6294a90acf8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      258. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:401b30fc-e143-4906-aae1-e5b5c190d4a8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      259. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07c8bb17-9bd4-4fab-994d-0412205b53b4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      260. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a78ab50-993d-4857-be10-be665e02b353 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      261. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a829dc3-b2d8-4d19-a579-0597217cec9b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      262. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:934244c6-243d-436e-ad6c-f7bd28e45a86 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      263. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:583ab038-7b6e-96f8-e063-6294a90adf47 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      264. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c22c3e6-2471-4b89-945b-f846c4d7884e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      265. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d35cd5ac-5ed6-2405-e053-2995a90a6946 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      266. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6670a64f-7f58-479f-b285-394abb753e2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      267. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd0e12c2-1986-4ca3-a809-d703a7542419 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      268. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b286fd1-8179-d87a-e063-6294a90a2f23 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      269. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1a9808d-31a5-4b63-afd0-d96d5a0ad7a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      270. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ea0b220-edbb-45eb-aeb3-65283f8489a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      271. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60b46f6d-efbc-487a-b672-b20df8b44cc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      272. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bec31452-b52b-4698-ba4c-0b614780ee84 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      273. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e89a7ff2-bd82-4fde-b2b7-3b9d0edf6fc8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      274. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a15d5dcc-63c4-4c06-ab91-5e22cdf234cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      275. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6702ed8f-4aaf-46fa-bf39-db75154aa44c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      276. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e286ed87-5fbc-4ff2-a05e-1f7fa658bbfc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      277. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ecb798a0-377d-4712-bb82-ec9d7116962f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      278. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38210141-bbdc-4186-b71f-54c72f794dca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      279. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4954172-5439-48fd-8348-8a2e0d2fee62 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      280. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6baeb5c-ca9c-4730-aeb8-8f8732e8ca3a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1200 mg, 2400 mg, 3600 mg, and 4800 mg/day given in 3 divided doses, respectively.
      281. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35004f84-90ae-45f0-a2ba-653dec507229 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      282. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b11dbff5-ceee-4a63-a093-f6efebdc2f6f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      283. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f455b415-12a2-4916-b826-246976a8af44 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      284. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ded42b88-94dd-462d-bcdf-7fd34d1e49c3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      285. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:176c5b60-93c2-4574-8b51-c15180912aaa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      286. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c18d9d06-f796-4eb7-8fd5-1de4ebb95439 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      287. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:223a9216-6e07-49b9-8faf-bb4e529a6ae5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      288. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ebf57adf-b066-2959-e053-2a95a90a961c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      289. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d294f6aa-ed82-90a2-e053-2995a90a2896 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      290. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:200b61d7-6e4c-923d-e063-6294a90a42cf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      291. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86c93d8b-6286-44e2-93dd-f1b10a5d83da (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      292. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3133c863-d33b-c9d7-e063-6294a90ae898 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      293. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25cf6c40-a239-4dd0-9cad-28da84d285db (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      294. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9c501c-24e4-da89-e053-2a95a90a64c6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      295. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8215da86-d7af-4980-b6d6-4bd46f6bfeaf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      296. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a975ebe-ae0a-446a-8a3d-2ca325e28f93 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      297. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3255245c-6ae6-46ab-a1c1-0b8d4d4cdaa2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      298. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be9a572d-e98a-41c1-83c5-859d9176dd1c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      299. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b20ee34a-7f2d-4d62-a161-898565f74547 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      300. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb726cb0-d422-48dd-a8ed-adbde812b005 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      301. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a70e2d-d3fd-4e32-95dd-7ee721d87388 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      302. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2343e3a1-82d0-4c70-a086-a01a0ce81ef3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      303. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abb56036-88df-4720-ba78-529971671545 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      304. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a75c9157-a1fc-44cc-89f8-c5a3742fb9ed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      305. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8b7e045-a7fe-8539-e053-2a95a90a40f8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      306. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54edd6f3-06c7-a0c7-e063-6394a90a8b4f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      307. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72729513-bd34-44f5-9f62-297ed25c4442 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      308. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:030e656a-e384-49ac-830f-32140c18112d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      309. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:725878fa-1e2f-4fee-a9e1-a6e102c79625 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      310. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78445dbf-c7cd-419f-a7be-72821e496628 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      311. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a2658d5-9b0e-4921-b4c5-4c89f1630d69 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      312. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59442de1-7cf0-35f6-e063-6294a90a57d7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      313. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41844c21-9e2a-4332-a8ff-9b71ae9032b0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      314. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16542ee6-0e0e-4d3c-8b32-60ff6ef48846 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      315. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8daa30f-1cb3-46aa-9b68-d9aa5b0a2105 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      316. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9814b76c-87c6-4746-b712-3269352a901b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      317. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63a5fc6d-ca57-4726-b70d-805ac023d959 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of Gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      318. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efb86e22-5a84-4b33-aad0-71dd5a2c6c8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      319. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0919fed8-e968-b5ac-e063-6294a90afbff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      320. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2eec52a1-9016-46dd-8b4c-8dab1d0aeece (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      321. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f651a143-3f88-49c9-b5c4-c9af55aea76a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      322. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c96b488-19bd-431e-af9a-b313ffd9eaae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      323. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37d4d465-19a5-46db-80dc-0b7334b3343a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      324. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22f2294f-352a-4515-87c8-a6ae46e61322 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      325. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f579665-afb7-4227-98c1-2eafee650504 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      326. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9944562-563a-423d-972c-f0313375d234 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      327. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17988b64-723c-488d-befd-3e4e4cc44bd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      328. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:934fefae-b895-427c-8798-4c5462b1ecc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      329. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e6ed5d2-40e0-1f06-e053-2a95a90aa40e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      330. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9f0852e-0c58-ba22-e053-2995a90adfa0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      331. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb0b6613-57d6-4e24-946f-f5f87c460cf0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      332. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc08e35d-ef5d-1dcd-e053-2a95a90ab5de (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      333. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afa28969-91ca-83fd-e053-2a95a90a656b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      334. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b395a14-0f8e-7f5b-e063-6294a90ab546 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      335. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f40a4ee4-ae8e-769c-e053-2a95a90a344e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      336. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52af51ab-6543-466b-848c-13c588c98789 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      337. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98bb408d-c402-4da6-8f9d-5de4833dedc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      338. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc1316b6-1fc4-4990-95a8-489881772876 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      339. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b3a4009-42f3-c84f-e063-6294a90a8068 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      340. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e1d17d5-d39c-4144-aac0-7c0d3bc9ec0d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      341. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dbd447f-4791-4c62-86b4-6f7928862785 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      342. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f95c01f-200e-bfd7-e063-6394a90abc38 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      343. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8998c1c-c359-6f01-e053-6294a90aebf4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      344. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5385e27c-f2fa-32d5-e063-6294a90a0a8c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      345. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba4d863d-be38-8cf5-e053-2995a90a69fb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      346. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      347. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eb2f6784-e7be-41b6-871b-2c3c961664ab (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      348. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a781649-3271-47a6-995f-50f91141a48a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      349. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb81fd89-b32b-4538-bf5c-ab02f65b3458 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      350. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:552912b2-be59-0333-e063-6394a90a85c0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      351. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3368bf70-d466-4765-b2b7-7fe967a8c2b7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      352. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1aa4690-57b5-4a3e-ac12-85f777dbd05e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      353. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:915cee37-536c-4761-bdb9-b96c7ee0f956 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      354. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43a3ec78-8235-4d46-a343-2f9226745a39 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      355. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:471b2d32-0cbd-aade-e063-6394a90a1696 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      356. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c3ac86f-b8f7-42bf-942a-db854d946e54 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1200 mg, 2400 mg, 3600 mg, and 4800 mg/day given in 3 divided doses, respectively.
      357. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec2e07e-5a8e-41e5-9ece-485431c7c4ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      358. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4c7388a-19d9-4e3a-83c9-4943fb855be4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      359. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:323dad14-ded9-4432-a265-c957e46cc6db (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1200 mg, 2400 mg, 3600 mg, or 4800 mg/day given in 3 divided doses, respectively.
      360. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35ac6b11-7b1c-47a0-a4ba-c193a0bb5b01 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      361. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e6b9d8f-9f9e-4760-96ea-fb8b0a3bbbdb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      362. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0cd96d1-b1ef-46ec-a5a3-9505b0811b8b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in three divided doses, respectively.
      363. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fb2233f-9152-4630-ab39-51a0cda7e5ca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      364. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01b810b7-f4c8-4412-bbc5-b9220d8770d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      365. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7646d5e-ca25-4ec5-9e4b-931edcb15a0e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      366. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec656c9-034f-4f14-9e6b-9779d41e1627 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      367. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56967a93-b3c0-4043-9241-585fc64e2624 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      368. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c09c66fd-cb31-41dd-b00b-acc58bd809f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      369. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97a1d45d-d5b3-4be7-9b3a-cb6f80f60291 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg, 1,200 mg, 2,400 mg, 3,600 mg, and 4,800 mg/day given in 3 divided doses, respectively.
      370. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:481e6b68-50e4-4594-9815-32580a84ab8c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      371. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec1c621b-db2a-1567-e053-2995a90a8695 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      372. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9cb5fe-7a2e-e0bc-e053-2a95a90a4470 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      373. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1ff94a9-69c4-486a-aab2-563c7ed244c8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      374. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ad67a07-59d0-4aaa-906b-befbbad8af31 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      375. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a619a14-0b63-4cba-80e7-474c9a1c90b9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      376. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5969f1a8-d6d5-4967-add5-4e2492354d7b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      377. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:765c7ce0-bbf5-4265-8ff0-1ba092c69865 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      378. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d25daaac-a8ab-4f12-acc2-4ec8fc97a2d4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      379. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a88edb00-2189-4c8d-9dd7-9fe1571775cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      380. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0510d04-460c-47d1-be72-0ee32c4ac640 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      381. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47214c7c-ba1b-9107-e063-6294a90a5431 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      382. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ad96553-73a4-4a9b-8a89-10a29b794ed3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      383. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3429322-c442-4146-bb68-bcc3a8d01552 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      384. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41dcc917-68d1-49f0-8223-44c21ca259ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      385. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2625c0ef-5295-41de-9e81-88001a6cbecc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      386. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03031adf-d36b-45ec-944e-dfce5a5de91a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      387. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7674ea5-276b-4bb3-821b-4ac05c9e64e6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      388. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9a05f0c-b5f0-422c-9d67-6d0efc921a74 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900; 1,200; 2,400; 3,600; and 4,800 mg/day given in 3 divided doses, respectively.
      389. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54dc347e-cba0-ea73-e063-6294a90ab436 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      390. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14d61caa-17ce-4fa2-90fb-1470f3864be8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      391. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ddcdff5-8f1f-bff3-e063-6294a90a1195 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      392. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43b67ae3-ac6f-48f5-8788-9ead08376864 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      393. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32169228-e85c-4dbf-8722-cd2f8e0f5d1a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      394. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7f21eaa-68ee-420c-9c98-e997cc73a297 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      395. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57492b91-1fe2-74ab-e063-6394a90a0b9e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      396. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e877a425-2b7f-4e43-a1f9-24019cbf9685 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.
      397. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc525ae4-9843-4038-a1b7-0d3543e2282c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1,200, 2,400, 3,600, and 4,800 mg/day given in 3 divided doses, respectively.
      398. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0e7a6c9-ae6c-4259-81ab-a37db54e3c80 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900, 1200, 2400, 3600, and 4800 mg/day given in 3 divided doses, respectively.
      399. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43cbff48-8219-41ba-b67d-3ae4544b78bb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Bioavailability of gabapentin is approximately 60%, 47%, 34%, 33%, and 27% following 900 mg/day, 1,200 mg/day, 2,400 mg/day, 3,600 mg/day, and 4,800 mg/day given in 3 divided doses, respectively.

  4. Projected row 664

    Medicine slug
    gabapentin
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    411
    Source count
    404
    Agreement rate
    0.980198
    Recorded readings

    1. 5 to 7 hours

      Numeric value
      5
      Unit
      hours
      Source records
      396

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 396 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b6db5ce9-bd4b-420d-88a7-df9d46144c81 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5073abda-321f-29d1-e063-6394a90a59ac (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c898711b-9a65-1816-e053-2995a90a855e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0eb27e64-1488-4083-82c7-cebb8c0605de (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77d1d90d-e124-4db7-b811-754d535e579c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a900bafb-8f49-4a01-ba7f-4fb228ec0253 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75418d32-6504-4cb4-b3a9-afa0eaf19b8d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b76955c-52a4-4026-b286-3da1112fe989 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fb79774-c2d4-47ba-9a16-eb367d0fdcff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba2a8352-5776-4edb-914e-ce1d18ccda32 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbc05ceb-2e69-3c37-e053-6394a90ac4f4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c89a68b6-6dc0-4624-e053-2a95a90a687e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b37b1dcc-c7e9-8845-e053-2995a90a089e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5b47f89-ed35-31de-e053-2a95a90a5554 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e90d2e3d-ec86-7d1d-e053-2995a90a9167 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c65253d-ca49-70eb-e063-6394a90a3cd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7fcce531-bf7c-43b6-bea9-8f0602842c53 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:969cccfc-e56a-49da-9d36-47c0c3fad7f8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2278ce1b-1c19-4ad2-89c6-4530f7b78ea7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5134369d-c7f6-4569-a425-d50e5a5d694f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:344d67fa-092e-4e71-b96a-25c71bfa6bb1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:781b0d62-a760-4371-8908-1f61329928a6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d592d828-8df1-480d-b179-bb9260a9c824 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function given gabapentin immediate release 1,200 to 3,000 mg/day, the drug elimination half-life (t 1/2 ) was 5 to 7 hours.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aaf3d6e-c6d5-89f5-e063-6394a90a9b77 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f350a4b-f294-4b98-b69f-3cc789e930ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b88b0cbc-c883-4d17-8f46-0e5bddc57835 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09736975-2493-4dbc-bbe0-cc56a1fec53f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ab9c18b-9568-4dcb-90b0-252aef8f8dc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc83432-8fce-6d2a-e053-2a95a90ae73f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38119f2e-33b3-4c3c-99b7-9335d8d280d4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7a29b99-ce23-950e-e053-2995a90a1934 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9f0cceb-b24e-4526-b873-fedd877d6bc6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e633cd0-5ee8-4a05-bcfc-0a80209bf27f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6beed8eb-446c-4575-8dc8-b798623d92c7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55292235-bf8f-46d0-e063-6294a90a91a5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81243958-cc5a-4ec0-a64d-71682f949d5f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:360d953b-4313-45ae-b933-296547d4577d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ac0622c-440a-49a0-974f-726e6ac72a0e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48037fc4-1aab-4ae8-aede-7c55b494877a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1006139-7dfc-4d87-a5a9-aeb380c32d24 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ddc7d92-9076-41cf-97ed-d9f9edc80298 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c585b71-5cfc-18d6-e063-6294a90a3dcf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74474aa4-4859-42d2-92d8-f23f18b34e04 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da8438e1-755b-4195-baa7-464f3d9ee5bd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bbfdedd7-2baf-4bc6-be59-548a5cf21752 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c8dca11-78ab-45c1-8bb2-89a41ea5dfa9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a072d5d2-8c75-59cc-e053-2a95a90ac0cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff28c5f1-da56-4072-a6fa-d689d4a6761b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40bb60c0-a2f3-4e7f-b13c-028c906c4852 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fc8e8b2-5d0e-4c72-9a46-6d312c3efac7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1749d731-bc8c-4374-b2a9-7c809c457f56 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b67b7865-df64-429a-9550-5333b9c713ea (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b2f38ef-0a0c-45cc-88ca-cc086bf80641 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39149f0e-30ed-4671-8be7-2a484f65d63b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79cd9dea-e7d0-44db-afba-964cb99f32b6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:645824d0-eb3d-442b-806d-36a70796cb8e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e7f602a-2c5f-4651-a228-5fc5bf249205 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c859e666-d510-426b-e053-2995a90a9a3c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f781d400-7304-5d3e-e053-6294a90ac572 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87b9171b-7d00-40fa-87ff-a717740efe8a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23eb133e-2f74-4219-9892-0a8e770ec032 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d3fc163-25f0-2c61-e053-2991aa0a76e9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c3b232a-3e9f-4249-9e5a-295482ee288a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:707ed63a-67ca-4a62-9cbe-cdeb5c4ab506 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47a22de2-ec66-45be-8648-89ed3ab6e67e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1373587e-807a-462a-bff6-8a7113ce9f0a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f982b95-4e84-4e0c-a543-747bc3dd7531 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e28ad3d-2d34-a5d0-e063-6294a90adb9e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35da078b-0da0-4757-a6c4-a9144c37e8e1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07aa1bcc-df05-44fa-92d4-63894e0e6cd6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c681c804-c6f3-d63b-e053-2995a90a6b8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b175f8d-7667-4bfe-8bb5-fd7441eed456 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08880902-bd44-41b6-866b-2cbad4c3f2b1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:691205ba-fa65-4bc9-ba20-7d361382cff9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58474aa7-7c6a-3a94-e063-6394a90a870b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7652adc6-1aad-4422-b85c-0c6b11c23b73 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97e47698-97c9-4eb5-a108-5850c2aa2818 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8de89818-805a-4a20-a9b1-48cf443b6315 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c78f528f-9192-4037-bfb9-ff5718ed26c5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7538e255-95df-4991-aae0-a90d709f1e95 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bae5032-f634-4d1e-b672-8a7e2bd6a5fa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa3ab216-372a-4a72-bfd1-88a1ffa31ba3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9c99dfa-f54d-9207-e053-2995a90ad43b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:506bf880-9564-404c-951a-703797ffdad8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c33c4d83-cc13-4104-9e24-d4cd40b17b70 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8a30eb7-3fc5-456a-bdae-3f4095bf2c2b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07871ab8-254b-e3c2-e063-6294a90a29ab (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cdbb381-88a2-5c5a-e063-6294a90a3e1e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64a65366-8577-48f2-9f8e-0332f126d3c1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7c1fd34-d615-43a2-8989-898fe11f90df (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f2ba3d6-6086-eaf2-e063-6294a90a7642 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b74a427c-9cc1-4b15-9ed2-cc891741fe67 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b26fd0c6-6aab-4957-8a32-cc7adb9b5fc9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ead7343-ab25-41b5-af4f-f903470e1dd9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c979f80b-d4b1-40f7-b878-b216db5f325d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67330eef-c976-4862-b1ae-20f30f43df76 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:266ef369-0a56-f225-e063-6294a90a495e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ddc1342-5c83-f562-e063-6294a90a29ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce0f0d7f-da6d-47da-a4ed-fb8f72902412 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd5c9279-a1e3-2a59-e053-2a95a90a33a2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5eff7ad8-0d31-4372-82a2-ac9f549d8796 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c49d34d-bb47-406b-8f2d-b4834b2ee9d0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07f07d15-ee91-8c2a-e063-6394a90a4624 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c85ae572-9893-629e-e053-2995a90a23fc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14b1840d-a2db-4eec-bc25-029e35b042e4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:172776c0-909e-49ce-bfe1-cf154a9458ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:100ff86c-56a8-4770-9db3-b9bc6b1bd2f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56378630-e7a7-4981-8212-8ea703a433d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54c09aa5-6724-480a-a115-c88484e39e93 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9ead7825-d11b-4e00-8533-328d097b8f83 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cb1ad6d-d389-4564-e063-6394a90a3644 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:743faa18-5e7c-4fcc-9781-4157450d90c4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc80b8b-da39-6fb9-e053-2a95a90a2d8e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1278512b-1493-db65-e063-6394a90ab161 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d544944-ea95-42e1-8c65-9e442437f0ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b73e9db-eddb-49ba-9778-01d39ece4d16 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a2aa696-7dac-4d03-916a-374b61a255b5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:185f264e-db32-41cd-b90d-519717b97850 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2dad630a-09d8-4f40-bdad-24e877a9ee38 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef37f2a0-3b83-4f71-91c0-6435161b483c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db57e37f-0a78-4c14-8768-a28bbf9fa0da (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffe5321d-3405-46d5-a75f-c51e8f8d87b1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:330ddc5d-c67c-33dc-e054-00144ff88e88 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:137b2b9a-9d42-48d0-913f-5dc146fb689a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4470a567-93a6-a293-e063-6394a90affc1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41d1ead3-046e-4abf-ae0a-cb126a1f5848 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:912d8697-b466-48dc-88d3-d2ba90e76644 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de990f96-96bc-406d-e053-2995a90abebb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      130. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13640281-26b4-402e-8f69-7c81cd6e0376 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      131. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4f21e97-5e55-44c9-9b31-5f79ac2eb512 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      132. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8604417-9d43-4d27-a7ce-d4120ff201f4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      133. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1eda6cc-d9b2-4df4-a09b-20eebded760f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      134. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:235a6954-318a-9e3a-e063-6394a90a0e21 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      135. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:021329d0-7d32-4fd8-81bf-a8b0d8b49e43 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      136. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd7adad2-e2f5-4b43-90a4-522bce0be5b3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      137. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:429a1bb5-babf-4f36-8264-46d71164f1c0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      138. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57383d2a-d2c7-bbdc-e063-6294a90ada98 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      139. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fce0c123-29d7-42bf-8c8d-8be1772e2d99 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      140. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:507bf6d0-e7a2-413d-9848-cd2445a1411d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      141. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5954a330-c225-00bd-e063-6294a90a7581 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      142. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d06380d0-c894-427e-b13e-5a8f9eb86a34 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      143. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:466273b1-c9fc-3930-c94b-aa11394d5140 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function given gabapentin immediate release 1,200 to 3,000 mg/day, the drug elimination half-life (t 1/2 ) was 5 to 7 hours.
      144. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:596eb696-7696-202e-e063-6394a90a2844 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      145. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6ff265b-569b-4f5c-8fdb-00b7ad4aac7c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      146. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6ecf5114-2ddc-4025-a36d-1884702dc22a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      147. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:081fd1de-acaa-4685-a053-4959d77b17e9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      148. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bff3beea-1f05-4e84-bcd2-d05782acddae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      149. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbeccab7-08aa-4da3-868f-b47a1f3d41ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      150. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f70c496-b58c-30f5-e054-00144ff8d46c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      151. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:561f53d5-5301-42b3-b372-f3d49d642a2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      152. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:92c4d589-533b-4fe4-833f-dd68cc1f7e66 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      153. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d77dae0-df76-4b7b-9690-713e9a60e3cd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      154. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed22b78e-93ff-4cb5-9c9c-2afe9b60dd2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      155. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7cb37f9-e1df-4e2a-bde5-9bfa0e040d7a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      156. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f38098ec-dd1a-405a-bbfb-bad62e4e7fa5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      157. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7a943ec-9a13-45ba-9bc5-18162b86b921 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      158. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbedccfb-0e27-4119-93b9-241c039e045a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      159. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:657349fb-41a9-4814-b4ac-4c5afbdde947 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      160. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:477691f5-0591-4544-840a-ac590e1f25a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      161. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b33c18ea-554d-3cfb-e053-2a95a90a2dd1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      162. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec1a01fe-5531-21df-e053-2a95a90a0561 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      163. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95757436-2093-41cf-a9a9-ef2f28ac096f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      164. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472bb279-bb4e-4246-b2a3-172483ba356b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      165. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f2e3ac5-5233-fd57-e063-6294a90a849e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function given gabapentin immediate release 1,200 to 3,000 mg/day, the drug elimination half-life (t 1/2 ) was 5 to 7 hours.
      166. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa246838-609c-4254-a8ec-d6f463a17960 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      167. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9d78138-e1e9-4107-9099-4910cb1422d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      168. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:618c948d-deee-44e2-98f0-e5232171dd50 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      169. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:685553b0-384e-400b-a8ae-612ceece8261 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      170. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc1998a7-7004-4688-8b5b-525041851d1d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      171. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e4eca9c-6a2c-4ede-a252-1a27094bf594 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      172. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bfee67dc-d2b1-4a00-92d9-a42be3189c74 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      173. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cc6615b-5447-9c0e-e063-6394a90a2883 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      174. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cb26d6e-7963-4fe5-903e-ab5180545066 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      175. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:798575b9-ddfa-4915-9574-626abbaf025f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      176. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ecc64b-f019-9fcb-e063-6294a90a00af (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      177. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5969871e-6c71-4c37-9d63-370718ccc80c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      178. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df9c7c84-a8d9-4da8-babe-c55c9420d4e6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      179. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff7de45-148b-4e96-88fd-6052bf75b5f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      180. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1af098ad-28b5-463f-8efa-24d70a77d64c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      181. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86b30e64-fe56-42b3-a0f8-d9ef5d4b8c49 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      182. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ddb3a54f-5224-4024-8804-b2a2f01d885e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      183. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97935fd9-1d4a-43b6-a5d9-de994591187b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      184. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47cd25f6-e123-9aaf-e063-6394a90aeedd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      185. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26aac429-a5cd-33cc-e063-6394a90aecc0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      186. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2da7d96-73ad-4f44-8784-160a384a0961 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      187. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f396ec70-826d-45c6-a27c-343c2fac878c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      188. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:167d8b87-506c-4293-9579-563feaa71583 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      189. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca8177ed-1f0d-436e-a5ac-f58b8f7cbb25 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      190. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:772d9e7a-3811-455a-99e6-f2a3d0769b9b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      191. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed3a0d48-2e98-44ee-8743-880d1221a480 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      192. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b404ab9-8a7e-49d4-920f-487875d14e45 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      193. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77754734-4125-42b1-97c8-458bcab2bcf1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      194. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45039bba-7a96-450c-95be-83a3aa4fcbd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      195. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b4395f2-9440-4b67-97cc-5d16f3bdd05e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      196. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ef99c3d-866a-438b-a340-8beba8d4c457 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      197. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9efd0261-9fc9-4dc9-8cf3-9110157ddfc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      198. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c79d94ec-117d-4fb6-845d-1954e3472bb0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      199. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78088f6a-06a3-422f-b336-4a57a24adc16 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      200. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2d9bd8c-3bb9-4945-8e61-7d2703d9008c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      201. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1fd95278-842f-4bf9-abd5-4d9aa858d36d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      202. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41ce952c-6c16-4b5d-adf7-9ea114e63eb3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      203. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30a2ed14-dcda-f972-e063-6294a90a417c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      204. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11645bd6-7cfe-49b2-9292-2e4b0dbb84ae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      205. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d3f27bf-3486-40fa-a4d3-5f0b2c6c0151 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      206. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eaf5e41e-8ed3-404e-84e0-392bebdbc0b7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      207. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:44f2b497-55b2-864f-e063-6294a90ad6d5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      208. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3865a6e3-112c-490c-82ac-35401336b16e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      209. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b86c81d9-9a4a-4847-be18-520e5cc5dc4b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      210. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02304deb-7b4a-452f-9b1a-64ca0aedbcc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      211. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4aa69d04-6b32-4764-a48b-ef5313dd95d3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      212. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75caca13-1432-4c0d-8d45-f029b0b2d417 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      213. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180b99a5-7d3d-4ee5-a0cc-1ae0ede646ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      214. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:152adf1d-ec0c-4561-bf80-e4c7da158723 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      215. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ea83c18-7107-41f4-8305-62725c1c45c8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      216. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:397fd6d3-317b-4b61-a52b-3a09ca1d88a4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      217. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36f74fdf-0dae-47a0-a7ea-e64ac91cd88f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      218. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a0a75ac-e121-477b-a9d1-d11f588afc9d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      219. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:722de2a9-38b3-4518-b262-ba0d1346d0ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      220. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:896c7782-1137-454b-aaa6-28f42c7413ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      221. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f31172a2-0ae9-49f2-b797-b26fe33f3f64 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      222. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d401e54-d4f5-43ba-b898-dd08fc3c7bfa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      223. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b44a3ab-4d06-205f-e063-6294a90af368 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      224. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a95f18e-0de4-4ce1-9f97-bc2e8a5bac6a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      225. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:500ee820-0378-6fc9-e063-6394a90a109c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      226. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:632cb507-5675-2392-0460-b09c0dd14650 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      227. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25befbfa-5125-4363-8306-f862e81c0a6f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      228. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5c9dd2c-b8ee-1406-e053-2995a90a0287 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      229. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af73fbd8-9731-e6bf-e053-2995a90af65d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      230. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b062f12c-a745-76d4-e053-2a95a90a3a1a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      231. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed219efc-84e3-5bdc-e053-2a95a90a56fc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      232. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fbd601f-df95-4a79-a7d3-c3505e23b913 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      233. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9bf87e4-5499-4dd7-a0c1-16025a718d14 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      234. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88ac51c4-5fa9-4c35-9c63-f26bcb101d4b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      235. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20e48004-d8b6-40fd-929b-b95087b4d85d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      236. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12f0c2ee-9a44-9778-e063-6294a90a3b58 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      237. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47f2a06f-4eac-4dca-aa2a-a36dd4daaea0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      238. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af62bb7e-162e-4e2a-8eb0-d50f66678707 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      239. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5769d849-4f27-4701-97ec-7e3ca07339d7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      240. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afa28969-91c8-83fd-e053-2a95a90a656b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      241. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:faa47fcd-2545-a946-e053-6294a90a05d2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      242. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13b87441-8fe1-40f5-8ffb-00dcd8cc90a6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      243. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:febf610e-e088-4797-e053-6294a90a3eb5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      244. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3133fc78-dd7a-880c-e063-6394a90a89e1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      245. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ce53f62-1738-43f4-9a2e-c5dc42a91d09 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function given gabapentin immediate release 1,200 to 3,000 mg/day, the drug elimination half-life (t 1/2 ) was 5 to 7 hours.
      246. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eeda97d-c3cd-65cd-e063-6394a90aae8b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      247. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e900fc4-a2b3-411f-9ab7-8dcbb97b697b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      248. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e847bcfa-f3de-404a-8a57-d8a414691e6a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      249. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e331641-ec26-4d76-b16b-a9863c767afe (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      250. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1045db4e-4c76-4a0d-bf12-019bd96a8f59 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      251. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:999f3685-2eac-467e-bed2-1d0c36aaf0ed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      252. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17a62334-209d-4dc1-867a-e5780196a2ca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      253. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d445d1d-02d1-4a59-b3b2-9ba5cd924c9a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      254. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f1203f4-2184-4e13-e063-6394a90a4330 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      255. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f93eaa4f-cc1a-10ab-e053-6394a90a5ffc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      256. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2bc65375-77b8-1e50-e063-6294a90acf8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      257. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:401b30fc-e143-4906-aae1-e5b5c190d4a8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      258. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07c8bb17-9bd4-4fab-994d-0412205b53b4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      259. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a78ab50-993d-4857-be10-be665e02b353 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      260. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a829dc3-b2d8-4d19-a579-0597217cec9b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      261. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:934244c6-243d-436e-ad6c-f7bd28e45a86 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      262. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:583ab038-7b6e-96f8-e063-6294a90adf47 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      263. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c22c3e6-2471-4b89-945b-f846c4d7884e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      264. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d35cd5ac-5ed6-2405-e053-2995a90a6946 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      265. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6670a64f-7f58-479f-b285-394abb753e2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      266. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd0e12c2-1986-4ca3-a809-d703a7542419 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      267. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b286fd1-8179-d87a-e063-6294a90a2f23 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      268. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1a9808d-31a5-4b63-afd0-d96d5a0ad7a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      269. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ea0b220-edbb-45eb-aeb3-65283f8489a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      270. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60b46f6d-efbc-487a-b672-b20df8b44cc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      271. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bec31452-b52b-4698-ba4c-0b614780ee84 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      272. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e89a7ff2-bd82-4fde-b2b7-3b9d0edf6fc8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      273. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a15d5dcc-63c4-4c06-ab91-5e22cdf234cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      274. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6702ed8f-4aaf-46fa-bf39-db75154aa44c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      275. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e286ed87-5fbc-4ff2-a05e-1f7fa658bbfc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      276. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ecb798a0-377d-4712-bb82-ec9d7116962f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      277. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38210141-bbdc-4186-b71f-54c72f794dca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      278. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4954172-5439-48fd-8348-8a2e0d2fee62 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      279. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6baeb5c-ca9c-4730-aeb8-8f8732e8ca3a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      280. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35004f84-90ae-45f0-a2ba-653dec507229 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      281. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b11dbff5-ceee-4a63-a093-f6efebdc2f6f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      282. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f455b415-12a2-4916-b826-246976a8af44 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      283. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ded42b88-94dd-462d-bcdf-7fd34d1e49c3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      284. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:176c5b60-93c2-4574-8b51-c15180912aaa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      285. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c18d9d06-f796-4eb7-8fd5-1de4ebb95439 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      286. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:223a9216-6e07-49b9-8faf-bb4e529a6ae5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      287. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ebf57adf-b066-2959-e053-2a95a90a961c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      288. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d294f6aa-ed82-90a2-e053-2995a90a2896 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      289. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:200b61d7-6e4c-923d-e063-6294a90a42cf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      290. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86c93d8b-6286-44e2-93dd-f1b10a5d83da (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      291. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3133c863-d33b-c9d7-e063-6294a90ae898 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      292. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25cf6c40-a239-4dd0-9cad-28da84d285db (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      293. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9c501c-24e4-da89-e053-2a95a90a64c6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      294. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8215da86-d7af-4980-b6d6-4bd46f6bfeaf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      295. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a975ebe-ae0a-446a-8a3d-2ca325e28f93 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      296. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3255245c-6ae6-46ab-a1c1-0b8d4d4cdaa2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      297. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be9a572d-e98a-41c1-83c5-859d9176dd1c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      298. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b20ee34a-7f2d-4d62-a161-898565f74547 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      299. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb726cb0-d422-48dd-a8ed-adbde812b005 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      300. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a70e2d-d3fd-4e32-95dd-7ee721d87388 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      301. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2343e3a1-82d0-4c70-a086-a01a0ce81ef3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      302. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abb56036-88df-4720-ba78-529971671545 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      303. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a75c9157-a1fc-44cc-89f8-c5a3742fb9ed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      304. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8b7e045-a7fe-8539-e053-2a95a90a40f8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      305. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54edd6f3-06c7-a0c7-e063-6394a90a8b4f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      306. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72729513-bd34-44f5-9f62-297ed25c4442 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      307. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:030e656a-e384-49ac-830f-32140c18112d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      308. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:725878fa-1e2f-4fee-a9e1-a6e102c79625 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      309. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78445dbf-c7cd-419f-a7be-72821e496628 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      310. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a2658d5-9b0e-4921-b4c5-4c89f1630d69 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      311. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59442de1-7cf0-35f6-e063-6294a90a57d7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      312. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41844c21-9e2a-4332-a8ff-9b71ae9032b0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      313. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16542ee6-0e0e-4d3c-8b32-60ff6ef48846 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      314. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8daa30f-1cb3-46aa-9b68-d9aa5b0a2105 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      315. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9814b76c-87c6-4746-b712-3269352a901b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      316. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63a5fc6d-ca57-4726-b70d-805ac023d959 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      317. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efb86e22-5a84-4b33-aad0-71dd5a2c6c8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      318. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0919fed8-e968-b5ac-e063-6294a90afbff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      319. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2eec52a1-9016-46dd-8b4c-8dab1d0aeece (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      320. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f651a143-3f88-49c9-b5c4-c9af55aea76a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      321. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c96b488-19bd-431e-af9a-b313ffd9eaae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      322. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37d4d465-19a5-46db-80dc-0b7334b3343a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      323. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22f2294f-352a-4515-87c8-a6ae46e61322 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      324. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f579665-afb7-4227-98c1-2eafee650504 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      325. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9944562-563a-423d-972c-f0313375d234 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      326. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17988b64-723c-488d-befd-3e4e4cc44bd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      327. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:934fefae-b895-427c-8798-4c5462b1ecc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      328. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e6ed5d2-40e0-1f06-e053-2a95a90aa40e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      329. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9f0852e-0c58-ba22-e053-2995a90adfa0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      330. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb0b6613-57d6-4e24-946f-f5f87c460cf0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      331. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc08e35d-ef5d-1dcd-e053-2a95a90ab5de (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      332. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afa28969-91ca-83fd-e053-2a95a90a656b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      333. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b395a14-0f8e-7f5b-e063-6294a90ab546 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      334. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f40a4ee4-ae8e-769c-e053-2a95a90a344e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      335. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52af51ab-6543-466b-848c-13c588c98789 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      336. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98bb408d-c402-4da6-8f9d-5de4833dedc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      337. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc1316b6-1fc4-4990-95a8-489881772876 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      338. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b3a4009-42f3-c84f-e063-6294a90a8068 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      339. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e1d17d5-d39c-4144-aac0-7c0d3bc9ec0d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      340. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dbd447f-4791-4c62-86b4-6f7928862785 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      341. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f95c01f-200e-bfd7-e063-6394a90abc38 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      342. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8998c1c-c359-6f01-e053-6294a90aebf4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      343. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5385e27c-f2fa-32d5-e063-6294a90a0a8c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      344. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba4d863d-be38-8cf5-e053-2995a90a69fb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      345. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      346. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eb2f6784-e7be-41b6-871b-2c3c961664ab (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      347. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a781649-3271-47a6-995f-50f91141a48a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      348. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb81fd89-b32b-4538-bf5c-ab02f65b3458 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      349. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:552912b2-be59-0333-e063-6394a90a85c0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      350. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3368bf70-d466-4765-b2b7-7fe967a8c2b7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      351. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1aa4690-57b5-4a3e-ac12-85f777dbd05e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      352. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:915cee37-536c-4761-bdb9-b96c7ee0f956 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      353. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43a3ec78-8235-4d46-a343-2f9226745a39 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      354. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:471b2d32-0cbd-aade-e063-6394a90a1696 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      355. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c3ac86f-b8f7-42bf-942a-db854d946e54 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      356. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec2e07e-5a8e-41e5-9ece-485431c7c4ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      357. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4c7388a-19d9-4e3a-83c9-4943fb855be4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      358. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:323dad14-ded9-4432-a265-c957e46cc6db (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      359. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35ac6b11-7b1c-47a0-a4ba-c193a0bb5b01 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      360. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e6b9d8f-9f9e-4760-96ea-fb8b0a3bbbdb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      361. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0cd96d1-b1ef-46ec-a5a3-9505b0811b8b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      362. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fb2233f-9152-4630-ab39-51a0cda7e5ca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      363. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01b810b7-f4c8-4412-bbc5-b9220d8770d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      364. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7646d5e-ca25-4ec5-9e4b-931edcb15a0e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      365. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec656c9-034f-4f14-9e6b-9779d41e1627 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      366. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56967a93-b3c0-4043-9241-585fc64e2624 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      367. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c09c66fd-cb31-41dd-b00b-acc58bd809f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      368. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97a1d45d-d5b3-4be7-9b3a-cb6f80f60291 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      369. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:481e6b68-50e4-4594-9815-32580a84ab8c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      370. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec1c621b-db2a-1567-e053-2995a90a8695 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      371. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9cb5fe-7a2e-e0bc-e053-2a95a90a4470 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      372. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1ff94a9-69c4-486a-aab2-563c7ed244c8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      373. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ad67a07-59d0-4aaa-906b-befbbad8af31 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      374. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a619a14-0b63-4cba-80e7-474c9a1c90b9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      375. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5969f1a8-d6d5-4967-add5-4e2492354d7b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      376. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d25daaac-a8ab-4f12-acc2-4ec8fc97a2d4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      377. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a88edb00-2189-4c8d-9dd7-9fe1571775cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      378. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0510d04-460c-47d1-be72-0ee32c4ac640 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      379. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47214c7c-ba1b-9107-e063-6294a90a5431 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      380. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ad96553-73a4-4a9b-8a89-10a29b794ed3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      381. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3429322-c442-4146-bb68-bcc3a8d01552 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      382. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41dcc917-68d1-49f0-8223-44c21ca259ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      383. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2625c0ef-5295-41de-9e81-88001a6cbecc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      384. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03031adf-d36b-45ec-944e-dfce5a5de91a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      385. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7674ea5-276b-4bb3-821b-4ac05c9e64e6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      386. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54dc347e-cba0-ea73-e063-6294a90ab436 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      387. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14d61caa-17ce-4fa2-90fb-1470f3864be8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      388. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ddcdff5-8f1f-bff3-e063-6294a90a1195 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      389. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43b67ae3-ac6f-48f5-8788-9ead08376864 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      390. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32169228-e85c-4dbf-8722-cd2f8e0f5d1a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      391. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7f21eaa-68ee-420c-9c98-e997cc73a297 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      392. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57492b91-1fe2-74ab-e063-6394a90a0b9e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      393. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e877a425-2b7f-4e43-a1f9-24019cbf9685 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      394. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc525ae4-9843-4038-a1b7-0d3543e2282c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      395. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0e7a6c9-ae6c-4259-81ab-a37db54e3c80 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.
      396. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43cbff48-8219-41ba-b67d-3ae4544b78bb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 to 7 hours and is unaltered by dose or following multiple dosing.

    2. 5 hours

      Numeric value
      5
      Unit
      hours
      Source records
      8

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 8 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81774da8-cb1d-4c7d-8550-35396850d5ff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 hours to 7 hours and is unaltered by dose or following multiple dosing.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3cfd04ab-e421-441f-a10e-e4dd1412974d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        In patients with normal renal function given gabapentin immediate release 1,200 to 3,000 mg/day, the drug elimination half-life (t 1/2 ) was 5 hours to 7 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d22ed424-f365-44ca-8ef9-a08255a90ae8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 hours to 7 hours and is unaltered by dose or following multiple dosing.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eeb19a5a-b31d-4df8-9546-0b2b5eb5db07 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 hours to 7 hours and is unaltered by dose or following multiple dosing.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:310ce005-5a24-489a-b23c-d42ab6a3bfed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 hours to 7 hours and is unaltered by dose or following multiple dosing.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7790d906-af26-4e60-bc6f-e906ec03cc24 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 hours to 7 hours and is unaltered by dose or following multiple dosing.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:765c7ce0-bbf5-4265-8ff0-1ba092c69865 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 hours to 7 hours and is unaltered by dose or following multiple dosing.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9a05f0c-b5f0-422c-9d67-6d0efc921a74 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Gabapentin elimination half-life is 5 hours to 7 hours and is unaltered by dose or following multiple dosing.

  5. Projected row 665

    Medicine slug
    gabapentin
    Compared field
    tMax
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    411
    Source count
    403
    Agreement rate
    0.970223
    Recorded readings

    1. 2 to 3 hours

      Numeric value
      2
      Unit
      hours
      Source records
      391

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 391 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b6db5ce9-bd4b-420d-88a7-df9d46144c81 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5073abda-321f-29d1-e063-6394a90a59ac (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c898711b-9a65-1816-e053-2995a90a855e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0eb27e64-1488-4083-82c7-cebb8c0605de (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77d1d90d-e124-4db7-b811-754d535e579c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a900bafb-8f49-4a01-ba7f-4fb228ec0253 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75418d32-6504-4cb4-b3a9-afa0eaf19b8d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b76955c-52a4-4026-b286-3da1112fe989 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fb79774-c2d4-47ba-9a16-eb367d0fdcff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba2a8352-5776-4edb-914e-ce1d18ccda32 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbc05ceb-2e69-3c37-e053-6394a90ac4f4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c89a68b6-6dc0-4624-e053-2a95a90a687e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b37b1dcc-c7e9-8845-e053-2995a90a089e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5b47f89-ed35-31de-e053-2a95a90a5554 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e90d2e3d-ec86-7d1d-e053-2995a90a9167 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c65253d-ca49-70eb-e063-6394a90a3cd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7fcce531-bf7c-43b6-bea9-8f0602842c53 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:969cccfc-e56a-49da-9d36-47c0c3fad7f8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2278ce1b-1c19-4ad2-89c6-4530f7b78ea7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5134369d-c7f6-4569-a425-d50e5a5d694f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:344d67fa-092e-4e71-b96a-25c71bfa6bb1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:781b0d62-a760-4371-8908-1f61329928a6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aaf3d6e-c6d5-89f5-e063-6394a90a9b77 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f350a4b-f294-4b98-b69f-3cc789e930ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b88b0cbc-c883-4d17-8f46-0e5bddc57835 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09736975-2493-4dbc-bbe0-cc56a1fec53f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ab9c18b-9568-4dcb-90b0-252aef8f8dc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc83432-8fce-6d2a-e053-2a95a90ae73f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38119f2e-33b3-4c3c-99b7-9335d8d280d4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7a29b99-ce23-950e-e053-2995a90a1934 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9f0cceb-b24e-4526-b873-fedd877d6bc6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e633cd0-5ee8-4a05-bcfc-0a80209bf27f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6beed8eb-446c-4575-8dc8-b798623d92c7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55292235-bf8f-46d0-e063-6294a90a91a5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81243958-cc5a-4ec0-a64d-71682f949d5f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:360d953b-4313-45ae-b933-296547d4577d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ac0622c-440a-49a0-974f-726e6ac72a0e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48037fc4-1aab-4ae8-aede-7c55b494877a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1006139-7dfc-4d87-a5a9-aeb380c32d24 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ddc7d92-9076-41cf-97ed-d9f9edc80298 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c585b71-5cfc-18d6-e063-6294a90a3dcf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da8438e1-755b-4195-baa7-464f3d9ee5bd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bbfdedd7-2baf-4bc6-be59-548a5cf21752 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c8dca11-78ab-45c1-8bb2-89a41ea5dfa9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a072d5d2-8c75-59cc-e053-2a95a90ac0cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff28c5f1-da56-4072-a6fa-d689d4a6761b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40bb60c0-a2f3-4e7f-b13c-028c906c4852 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fc8e8b2-5d0e-4c72-9a46-6d312c3efac7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1749d731-bc8c-4374-b2a9-7c809c457f56 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b67b7865-df64-429a-9550-5333b9c713ea (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b2f38ef-0a0c-45cc-88ca-cc086bf80641 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39149f0e-30ed-4671-8be7-2a484f65d63b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79cd9dea-e7d0-44db-afba-964cb99f32b6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:645824d0-eb3d-442b-806d-36a70796cb8e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e7f602a-2c5f-4651-a228-5fc5bf249205 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c859e666-d510-426b-e053-2995a90a9a3c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f781d400-7304-5d3e-e053-6294a90ac572 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87b9171b-7d00-40fa-87ff-a717740efe8a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23eb133e-2f74-4219-9892-0a8e770ec032 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d3fc163-25f0-2c61-e053-2991aa0a76e9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c3b232a-3e9f-4249-9e5a-295482ee288a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:707ed63a-67ca-4a62-9cbe-cdeb5c4ab506 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47a22de2-ec66-45be-8648-89ed3ab6e67e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1373587e-807a-462a-bff6-8a7113ce9f0a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f982b95-4e84-4e0c-a543-747bc3dd7531 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e28ad3d-2d34-a5d0-e063-6294a90adb9e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35da078b-0da0-4757-a6c4-a9144c37e8e1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07aa1bcc-df05-44fa-92d4-63894e0e6cd6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c681c804-c6f3-d63b-e053-2995a90a6b8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b175f8d-7667-4bfe-8bb5-fd7441eed456 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08880902-bd44-41b6-866b-2cbad4c3f2b1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:691205ba-fa65-4bc9-ba20-7d361382cff9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58474aa7-7c6a-3a94-e063-6394a90a870b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7652adc6-1aad-4422-b85c-0c6b11c23b73 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97e47698-97c9-4eb5-a108-5850c2aa2818 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8de89818-805a-4a20-a9b1-48cf443b6315 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c78f528f-9192-4037-bfb9-ff5718ed26c5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7538e255-95df-4991-aae0-a90d709f1e95 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bae5032-f634-4d1e-b672-8a7e2bd6a5fa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa3ab216-372a-4a72-bfd1-88a1ffa31ba3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9c99dfa-f54d-9207-e053-2995a90ad43b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:506bf880-9564-404c-951a-703797ffdad8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours post-dose.
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c33c4d83-cc13-4104-9e24-d4cd40b17b70 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8a30eb7-3fc5-456a-bdae-3f4095bf2c2b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07871ab8-254b-e3c2-e063-6294a90a29ab (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cdbb381-88a2-5c5a-e063-6294a90a3e1e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64a65366-8577-48f2-9f8e-0332f126d3c1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7c1fd34-d615-43a2-8989-898fe11f90df (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f2ba3d6-6086-eaf2-e063-6294a90a7642 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b74a427c-9cc1-4b15-9ed2-cc891741fe67 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b26fd0c6-6aab-4957-8a32-cc7adb9b5fc9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ead7343-ab25-41b5-af4f-f903470e1dd9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c979f80b-d4b1-40f7-b878-b216db5f325d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67330eef-c976-4862-b1ae-20f30f43df76 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:266ef369-0a56-f225-e063-6294a90a495e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ddc1342-5c83-f562-e063-6294a90a29ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce0f0d7f-da6d-47da-a4ed-fb8f72902412 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd5c9279-a1e3-2a59-e053-2a95a90a33a2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5eff7ad8-0d31-4372-82a2-ac9f549d8796 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c49d34d-bb47-406b-8f2d-b4834b2ee9d0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07f07d15-ee91-8c2a-e063-6394a90a4624 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c85ae572-9893-629e-e053-2995a90a23fc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14b1840d-a2db-4eec-bc25-029e35b042e4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:172776c0-909e-49ce-bfe1-cf154a9458ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:100ff86c-56a8-4770-9db3-b9bc6b1bd2f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56378630-e7a7-4981-8212-8ea703a433d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54c09aa5-6724-480a-a115-c88484e39e93 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9ead7825-d11b-4e00-8533-328d097b8f83 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cb1ad6d-d389-4564-e063-6394a90a3644 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:743faa18-5e7c-4fcc-9781-4157450d90c4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc80b8b-da39-6fb9-e053-2a95a90a2d8e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1278512b-1493-db65-e063-6394a90ab161 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d544944-ea95-42e1-8c65-9e442437f0ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b73e9db-eddb-49ba-9778-01d39ece4d16 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a2aa696-7dac-4d03-916a-374b61a255b5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:185f264e-db32-41cd-b90d-519717b97850 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2dad630a-09d8-4f40-bdad-24e877a9ee38 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef37f2a0-3b83-4f71-91c0-6435161b483c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db57e37f-0a78-4c14-8768-a28bbf9fa0da (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffe5321d-3405-46d5-a75f-c51e8f8d87b1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:330ddc5d-c67c-33dc-e054-00144ff88e88 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:137b2b9a-9d42-48d0-913f-5dc146fb689a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4470a567-93a6-a293-e063-6394a90affc1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41d1ead3-046e-4abf-ae0a-cb126a1f5848 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:912d8697-b466-48dc-88d3-d2ba90e76644 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de990f96-96bc-406d-e053-2995a90abebb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13640281-26b4-402e-8f69-7c81cd6e0376 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4f21e97-5e55-44c9-9b31-5f79ac2eb512 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      130. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8604417-9d43-4d27-a7ce-d4120ff201f4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      131. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1eda6cc-d9b2-4df4-a09b-20eebded760f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      132. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:235a6954-318a-9e3a-e063-6394a90a0e21 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      133. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:021329d0-7d32-4fd8-81bf-a8b0d8b49e43 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      134. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd7adad2-e2f5-4b43-90a4-522bce0be5b3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      135. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:429a1bb5-babf-4f36-8264-46d71164f1c0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      136. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57383d2a-d2c7-bbdc-e063-6294a90ada98 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      137. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fce0c123-29d7-42bf-8c8d-8be1772e2d99 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      138. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:507bf6d0-e7a2-413d-9848-cd2445a1411d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours post-dose.
      139. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5954a330-c225-00bd-e063-6294a90a7581 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      140. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d06380d0-c894-427e-b13e-5a8f9eb86a34 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      141. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:596eb696-7696-202e-e063-6394a90a2844 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      142. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6ff265b-569b-4f5c-8fdb-00b7ad4aac7c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      143. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6ecf5114-2ddc-4025-a36d-1884702dc22a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      144. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:081fd1de-acaa-4685-a053-4959d77b17e9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      145. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bff3beea-1f05-4e84-bcd2-d05782acddae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      146. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbeccab7-08aa-4da3-868f-b47a1f3d41ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      147. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f70c496-b58c-30f5-e054-00144ff8d46c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      148. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:561f53d5-5301-42b3-b372-f3d49d642a2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      149. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:92c4d589-533b-4fe4-833f-dd68cc1f7e66 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      150. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d77dae0-df76-4b7b-9690-713e9a60e3cd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      151. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed22b78e-93ff-4cb5-9c9c-2afe9b60dd2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      152. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7cb37f9-e1df-4e2a-bde5-9bfa0e040d7a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      153. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f38098ec-dd1a-405a-bbfb-bad62e4e7fa5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      154. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7a943ec-9a13-45ba-9bc5-18162b86b921 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      155. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbedccfb-0e27-4119-93b9-241c039e045a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours post-dose.
      156. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:657349fb-41a9-4814-b4ac-4c5afbdde947 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours post-dose.
      157. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:477691f5-0591-4544-840a-ac590e1f25a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours post-dose.
      158. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b33c18ea-554d-3cfb-e053-2a95a90a2dd1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      159. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec1a01fe-5531-21df-e053-2a95a90a0561 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      160. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95757436-2093-41cf-a9a9-ef2f28ac096f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      161. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472bb279-bb4e-4246-b2a3-172483ba356b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      162. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa246838-609c-4254-a8ec-d6f463a17960 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      163. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9d78138-e1e9-4107-9099-4910cb1422d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      164. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:618c948d-deee-44e2-98f0-e5232171dd50 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      165. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:685553b0-384e-400b-a8ae-612ceece8261 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      166. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc1998a7-7004-4688-8b5b-525041851d1d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      167. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e4eca9c-6a2c-4ede-a252-1a27094bf594 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      168. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bfee67dc-d2b1-4a00-92d9-a42be3189c74 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      169. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cc6615b-5447-9c0e-e063-6394a90a2883 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      170. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cb26d6e-7963-4fe5-903e-ab5180545066 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      171. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:798575b9-ddfa-4915-9574-626abbaf025f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      172. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ecc64b-f019-9fcb-e063-6294a90a00af (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      173. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5969871e-6c71-4c37-9d63-370718ccc80c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      174. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df9c7c84-a8d9-4da8-babe-c55c9420d4e6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      175. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff7de45-148b-4e96-88fd-6052bf75b5f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      176. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1af098ad-28b5-463f-8efa-24d70a77d64c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      177. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86b30e64-fe56-42b3-a0f8-d9ef5d4b8c49 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      178. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ddb3a54f-5224-4024-8804-b2a2f01d885e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      179. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97935fd9-1d4a-43b6-a5d9-de994591187b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      180. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47cd25f6-e123-9aaf-e063-6394a90aeedd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      181. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26aac429-a5cd-33cc-e063-6394a90aecc0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      182. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2da7d96-73ad-4f44-8784-160a384a0961 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      183. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f396ec70-826d-45c6-a27c-343c2fac878c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      184. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:167d8b87-506c-4293-9579-563feaa71583 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      185. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca8177ed-1f0d-436e-a5ac-f58b8f7cbb25 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      186. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:772d9e7a-3811-455a-99e6-f2a3d0769b9b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      187. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed3a0d48-2e98-44ee-8743-880d1221a480 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      188. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b404ab9-8a7e-49d4-920f-487875d14e45 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours post-dose.
      189. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77754734-4125-42b1-97c8-458bcab2bcf1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      190. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45039bba-7a96-450c-95be-83a3aa4fcbd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      191. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b4395f2-9440-4b67-97cc-5d16f3bdd05e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      192. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ef99c3d-866a-438b-a340-8beba8d4c457 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours post dose.
      193. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9efd0261-9fc9-4dc9-8cf3-9110157ddfc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      194. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c79d94ec-117d-4fb6-845d-1954e3472bb0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      195. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78088f6a-06a3-422f-b336-4a57a24adc16 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      196. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2d9bd8c-3bb9-4945-8e61-7d2703d9008c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      197. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1fd95278-842f-4bf9-abd5-4d9aa858d36d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      198. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41ce952c-6c16-4b5d-adf7-9ea114e63eb3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      199. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30a2ed14-dcda-f972-e063-6294a90a417c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      200. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11645bd6-7cfe-49b2-9292-2e4b0dbb84ae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      201. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d3f27bf-3486-40fa-a4d3-5f0b2c6c0151 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      202. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eaf5e41e-8ed3-404e-84e0-392bebdbc0b7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      203. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:44f2b497-55b2-864f-e063-6294a90ad6d5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      204. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3865a6e3-112c-490c-82ac-35401336b16e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      205. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b86c81d9-9a4a-4847-be18-520e5cc5dc4b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      206. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02304deb-7b4a-452f-9b1a-64ca0aedbcc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      207. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4aa69d04-6b32-4764-a48b-ef5313dd95d3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      208. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75caca13-1432-4c0d-8d45-f029b0b2d417 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      209. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180b99a5-7d3d-4ee5-a0cc-1ae0ede646ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      210. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:152adf1d-ec0c-4561-bf80-e4c7da158723 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      211. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ea83c18-7107-41f4-8305-62725c1c45c8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      212. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:397fd6d3-317b-4b61-a52b-3a09ca1d88a4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      213. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36f74fdf-0dae-47a0-a7ea-e64ac91cd88f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      214. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a0a75ac-e121-477b-a9d1-d11f588afc9d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      215. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:722de2a9-38b3-4518-b262-ba0d1346d0ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      216. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:896c7782-1137-454b-aaa6-28f42c7413ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      217. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f31172a2-0ae9-49f2-b797-b26fe33f3f64 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      218. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d401e54-d4f5-43ba-b898-dd08fc3c7bfa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      219. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b44a3ab-4d06-205f-e063-6294a90af368 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      220. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a95f18e-0de4-4ce1-9f97-bc2e8a5bac6a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      221. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:500ee820-0378-6fc9-e063-6394a90a109c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      222. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:632cb507-5675-2392-0460-b09c0dd14650 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      223. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25befbfa-5125-4363-8306-f862e81c0a6f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      224. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5c9dd2c-b8ee-1406-e053-2995a90a0287 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      225. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af73fbd8-9731-e6bf-e053-2995a90af65d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      226. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b062f12c-a745-76d4-e053-2a95a90a3a1a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      227. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed219efc-84e3-5bdc-e053-2a95a90a56fc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      228. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fbd601f-df95-4a79-a7d3-c3505e23b913 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      229. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9bf87e4-5499-4dd7-a0c1-16025a718d14 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      230. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88ac51c4-5fa9-4c35-9c63-f26bcb101d4b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      231. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20e48004-d8b6-40fd-929b-b95087b4d85d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      232. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12f0c2ee-9a44-9778-e063-6294a90a3b58 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      233. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47f2a06f-4eac-4dca-aa2a-a36dd4daaea0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      234. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af62bb7e-162e-4e2a-8eb0-d50f66678707 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      235. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5769d849-4f27-4701-97ec-7e3ca07339d7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      236. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afa28969-91c8-83fd-e053-2a95a90a656b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      237. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:faa47fcd-2545-a946-e053-6294a90a05d2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      238. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13b87441-8fe1-40f5-8ffb-00dcd8cc90a6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      239. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:febf610e-e088-4797-e053-6294a90a3eb5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      240. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3133fc78-dd7a-880c-e063-6394a90a89e1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      241. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eeda97d-c3cd-65cd-e063-6394a90aae8b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      242. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e900fc4-a2b3-411f-9ab7-8dcbb97b697b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      243. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e847bcfa-f3de-404a-8a57-d8a414691e6a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      244. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e331641-ec26-4d76-b16b-a9863c767afe (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      245. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1045db4e-4c76-4a0d-bf12-019bd96a8f59 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      246. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:999f3685-2eac-467e-bed2-1d0c36aaf0ed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      247. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17a62334-209d-4dc1-867a-e5780196a2ca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      248. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d445d1d-02d1-4a59-b3b2-9ba5cd924c9a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      249. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f1203f4-2184-4e13-e063-6394a90a4330 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      250. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f93eaa4f-cc1a-10ab-e053-6394a90a5ffc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      251. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2bc65375-77b8-1e50-e063-6294a90acf8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      252. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:401b30fc-e143-4906-aae1-e5b5c190d4a8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      253. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07c8bb17-9bd4-4fab-994d-0412205b53b4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      254. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a78ab50-993d-4857-be10-be665e02b353 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      255. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a829dc3-b2d8-4d19-a579-0597217cec9b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      256. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:934244c6-243d-436e-ad6c-f7bd28e45a86 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      257. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:583ab038-7b6e-96f8-e063-6294a90adf47 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      258. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c22c3e6-2471-4b89-945b-f846c4d7884e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      259. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d35cd5ac-5ed6-2405-e053-2995a90a6946 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      260. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6670a64f-7f58-479f-b285-394abb753e2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      261. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd0e12c2-1986-4ca3-a809-d703a7542419 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      262. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b286fd1-8179-d87a-e063-6294a90a2f23 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      263. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1a9808d-31a5-4b63-afd0-d96d5a0ad7a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      264. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ea0b220-edbb-45eb-aeb3-65283f8489a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      265. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60b46f6d-efbc-487a-b672-b20df8b44cc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      266. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bec31452-b52b-4698-ba4c-0b614780ee84 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      267. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e89a7ff2-bd82-4fde-b2b7-3b9d0edf6fc8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      268. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a15d5dcc-63c4-4c06-ab91-5e22cdf234cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours post-dose.
      269. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6702ed8f-4aaf-46fa-bf39-db75154aa44c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      270. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e286ed87-5fbc-4ff2-a05e-1f7fa658bbfc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      271. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ecb798a0-377d-4712-bb82-ec9d7116962f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      272. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38210141-bbdc-4186-b71f-54c72f794dca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      273. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4954172-5439-48fd-8348-8a2e0d2fee62 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      274. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6baeb5c-ca9c-4730-aeb8-8f8732e8ca3a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      275. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35004f84-90ae-45f0-a2ba-653dec507229 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      276. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b11dbff5-ceee-4a63-a093-f6efebdc2f6f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      277. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f455b415-12a2-4916-b826-246976a8af44 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      278. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ded42b88-94dd-462d-bcdf-7fd34d1e49c3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      279. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:176c5b60-93c2-4574-8b51-c15180912aaa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      280. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c18d9d06-f796-4eb7-8fd5-1de4ebb95439 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      281. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:223a9216-6e07-49b9-8faf-bb4e529a6ae5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      282. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ebf57adf-b066-2959-e053-2a95a90a961c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      283. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d294f6aa-ed82-90a2-e053-2995a90a2896 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      284. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:200b61d7-6e4c-923d-e063-6294a90a42cf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      285. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86c93d8b-6286-44e2-93dd-f1b10a5d83da (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      286. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3133c863-d33b-c9d7-e063-6294a90ae898 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      287. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25cf6c40-a239-4dd0-9cad-28da84d285db (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      288. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9c501c-24e4-da89-e053-2a95a90a64c6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      289. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8215da86-d7af-4980-b6d6-4bd46f6bfeaf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      290. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a975ebe-ae0a-446a-8a3d-2ca325e28f93 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      291. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3255245c-6ae6-46ab-a1c1-0b8d4d4cdaa2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      292. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be9a572d-e98a-41c1-83c5-859d9176dd1c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      293. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b20ee34a-7f2d-4d62-a161-898565f74547 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      294. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb726cb0-d422-48dd-a8ed-adbde812b005 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      295. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a70e2d-d3fd-4e32-95dd-7ee721d87388 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      296. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2343e3a1-82d0-4c70-a086-a01a0ce81ef3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      297. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abb56036-88df-4720-ba78-529971671545 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      298. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a75c9157-a1fc-44cc-89f8-c5a3742fb9ed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      299. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8b7e045-a7fe-8539-e053-2a95a90a40f8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      300. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54edd6f3-06c7-a0c7-e063-6394a90a8b4f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      301. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72729513-bd34-44f5-9f62-297ed25c4442 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      302. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:030e656a-e384-49ac-830f-32140c18112d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      303. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:725878fa-1e2f-4fee-a9e1-a6e102c79625 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      304. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78445dbf-c7cd-419f-a7be-72821e496628 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      305. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a2658d5-9b0e-4921-b4c5-4c89f1630d69 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      306. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59442de1-7cf0-35f6-e063-6294a90a57d7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      307. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41844c21-9e2a-4332-a8ff-9b71ae9032b0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      308. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16542ee6-0e0e-4d3c-8b32-60ff6ef48846 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      309. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8daa30f-1cb3-46aa-9b68-d9aa5b0a2105 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      310. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9814b76c-87c6-4746-b712-3269352a901b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      311. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63a5fc6d-ca57-4726-b70d-805ac023d959 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      312. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efb86e22-5a84-4b33-aad0-71dd5a2c6c8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      313. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0919fed8-e968-b5ac-e063-6294a90afbff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      314. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2eec52a1-9016-46dd-8b4c-8dab1d0aeece (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      315. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f651a143-3f88-49c9-b5c4-c9af55aea76a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      316. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c96b488-19bd-431e-af9a-b313ffd9eaae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      317. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37d4d465-19a5-46db-80dc-0b7334b3343a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      318. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22f2294f-352a-4515-87c8-a6ae46e61322 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      319. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f579665-afb7-4227-98c1-2eafee650504 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      320. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9944562-563a-423d-972c-f0313375d234 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      321. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17988b64-723c-488d-befd-3e4e4cc44bd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      322. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:934fefae-b895-427c-8798-4c5462b1ecc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      323. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e6ed5d2-40e0-1f06-e053-2a95a90aa40e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      324. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9f0852e-0c58-ba22-e053-2995a90adfa0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      325. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb0b6613-57d6-4e24-946f-f5f87c460cf0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      326. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc08e35d-ef5d-1dcd-e053-2a95a90ab5de (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      327. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afa28969-91ca-83fd-e053-2a95a90a656b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      328. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b395a14-0f8e-7f5b-e063-6294a90ab546 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      329. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f40a4ee4-ae8e-769c-e053-2a95a90a344e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      330. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52af51ab-6543-466b-848c-13c588c98789 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      331. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98bb408d-c402-4da6-8f9d-5de4833dedc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      332. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc1316b6-1fc4-4990-95a8-489881772876 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      333. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b3a4009-42f3-c84f-e063-6294a90a8068 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      334. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e1d17d5-d39c-4144-aac0-7c0d3bc9ec0d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      335. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dbd447f-4791-4c62-86b4-6f7928862785 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      336. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f95c01f-200e-bfd7-e063-6394a90abc38 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      337. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8998c1c-c359-6f01-e053-6294a90aebf4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      338. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5385e27c-f2fa-32d5-e063-6294a90a0a8c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      339. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba4d863d-be38-8cf5-e053-2995a90a69fb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      340. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      341. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eb2f6784-e7be-41b6-871b-2c3c961664ab (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      342. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a781649-3271-47a6-995f-50f91141a48a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      343. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb81fd89-b32b-4538-bf5c-ab02f65b3458 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      344. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:552912b2-be59-0333-e063-6394a90a85c0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      345. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3368bf70-d466-4765-b2b7-7fe967a8c2b7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      346. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1aa4690-57b5-4a3e-ac12-85f777dbd05e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      347. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:915cee37-536c-4761-bdb9-b96c7ee0f956 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      348. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43a3ec78-8235-4d46-a343-2f9226745a39 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      349. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:471b2d32-0cbd-aade-e063-6394a90a1696 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      350. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c3ac86f-b8f7-42bf-942a-db854d946e54 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      351. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec2e07e-5a8e-41e5-9ece-485431c7c4ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      352. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4c7388a-19d9-4e3a-83c9-4943fb855be4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      353. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:323dad14-ded9-4432-a265-c957e46cc6db (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      354. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35ac6b11-7b1c-47a0-a4ba-c193a0bb5b01 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      355. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e6b9d8f-9f9e-4760-96ea-fb8b0a3bbbdb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      356. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0cd96d1-b1ef-46ec-a5a3-9505b0811b8b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      357. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fb2233f-9152-4630-ab39-51a0cda7e5ca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      358. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01b810b7-f4c8-4412-bbc5-b9220d8770d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      359. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7646d5e-ca25-4ec5-9e4b-931edcb15a0e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      360. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec656c9-034f-4f14-9e6b-9779d41e1627 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      361. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56967a93-b3c0-4043-9241-585fc64e2624 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      362. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c09c66fd-cb31-41dd-b00b-acc58bd809f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      363. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97a1d45d-d5b3-4be7-9b3a-cb6f80f60291 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      364. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:481e6b68-50e4-4594-9815-32580a84ab8c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      365. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec1c621b-db2a-1567-e053-2995a90a8695 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      366. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9cb5fe-7a2e-e0bc-e053-2a95a90a4470 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      367. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1ff94a9-69c4-486a-aab2-563c7ed244c8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      368. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ad67a07-59d0-4aaa-906b-befbbad8af31 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      369. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a619a14-0b63-4cba-80e7-474c9a1c90b9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      370. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5969f1a8-d6d5-4967-add5-4e2492354d7b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      371. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d25daaac-a8ab-4f12-acc2-4ec8fc97a2d4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      372. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a88edb00-2189-4c8d-9dd7-9fe1571775cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      373. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0510d04-460c-47d1-be72-0ee32c4ac640 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      374. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47214c7c-ba1b-9107-e063-6294a90a5431 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      375. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ad96553-73a4-4a9b-8a89-10a29b794ed3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      376. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3429322-c442-4146-bb68-bcc3a8d01552 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      377. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41dcc917-68d1-49f0-8223-44c21ca259ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      378. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2625c0ef-5295-41de-9e81-88001a6cbecc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      379. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03031adf-d36b-45ec-944e-dfce5a5de91a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      380. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7674ea5-276b-4bb3-821b-4ac05c9e64e6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      381. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54dc347e-cba0-ea73-e063-6294a90ab436 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours post-dose.
      382. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14d61caa-17ce-4fa2-90fb-1470f3864be8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      383. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ddcdff5-8f1f-bff3-e063-6294a90a1195 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      384. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43b67ae3-ac6f-48f5-8788-9ead08376864 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      385. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32169228-e85c-4dbf-8722-cd2f8e0f5d1a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      386. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7f21eaa-68ee-420c-9c98-e997cc73a297 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      387. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57492b91-1fe2-74ab-e063-6394a90a0b9e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      388. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e877a425-2b7f-4e43-a1f9-24019cbf9685 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      389. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc525ae4-9843-4038-a1b7-0d3543e2282c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      390. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0e7a6c9-ae6c-4259-81ab-a37db54e3c80 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.
      391. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43cbff48-8219-41ba-b67d-3ae4544b78bb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 to 3 hours postdose.

    2. 2 hours

      Numeric value
      2
      Unit
      hours
      Source records
      7

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 7 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81774da8-cb1d-4c7d-8550-35396850d5ff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 hours to 3 hours postdose.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d22ed424-f365-44ca-8ef9-a08255a90ae8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 hours to 3 hours postdose.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eeb19a5a-b31d-4df8-9546-0b2b5eb5db07 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 hours to 3 hours postdose.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:310ce005-5a24-489a-b23c-d42ab6a3bfed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 hours to 3 hours postdose.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7790d906-af26-4e60-bc6f-e906ec03cc24 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 hours to 3 hours postdose.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:765c7ce0-bbf5-4265-8ff0-1ba092c69865 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 hours to 3 hours postdose.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9a05f0c-b5f0-422c-9d67-6d0efc921a74 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Peak plasma concentrations were similar across the entire age group and occurred 2 hours to 3 hours postdose.

    3. 8 hours

      Numeric value
      8
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d592d828-8df1-480d-b179-bb9260a9c824 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Time to reach maximum plasma concentration (T max ) for gabapentin tablets is 8 hours, which is about 4 to 6 hours longer compared to gabapentin immediate release.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3cfd04ab-e421-441f-a10e-e4dd1412974d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Time to reach maximum plasma concentration (T max ) for gabapentin is 8 hours, which is about 4 hours to 6 hours longer compared to gabapentin immediate release.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:466273b1-c9fc-3930-c94b-aa11394d5140 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Time to reach maximum plasma concentration (T max ) for GRALISE is 8 hours, which is about 4-6 hours longer compared to gabapentin immediate release.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f2e3ac5-5233-fd57-e063-6294a90a849e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Time to reach maximum plasma concentration (T max ) for gabapentin tablets (Once-Daily) is 8 hours, which is about 4-6 hours longer compared to gabapentin immediate release.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ce53f62-1738-43f4-9a2e-c5dc42a91d09 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        Time to reach maximum plasma concentration (T max ) for gabapentin is 8 hours, which is about 4 to 6 hours longer compared to gabapentin immediate release.

  6. Projected row 666

    Medicine slug
    gabapentin
    Compared field
    volumeOfDistribution
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    411
    Source count
    404
    Agreement rate
    1
    Recorded readings

    1. 58±6 L

      Numeric value
      58
      Unit
      L
      Source records
      404

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 404 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b6db5ce9-bd4b-420d-88a7-df9d46144c81 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5073abda-321f-29d1-e063-6394a90a59ac (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c898711b-9a65-1816-e053-2995a90a855e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0eb27e64-1488-4083-82c7-cebb8c0605de (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77d1d90d-e124-4db7-b811-754d535e579c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a900bafb-8f49-4a01-ba7f-4fb228ec0253 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75418d32-6504-4cb4-b3a9-afa0eaf19b8d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b76955c-52a4-4026-b286-3da1112fe989 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      9. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fb79774-c2d4-47ba-9a16-eb367d0fdcff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      10. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba2a8352-5776-4edb-914e-ce1d18ccda32 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      11. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbc05ceb-2e69-3c37-e053-6394a90ac4f4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      12. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c89a68b6-6dc0-4624-e053-2a95a90a687e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      13. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b37b1dcc-c7e9-8845-e053-2995a90a089e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      14. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a5b47f89-ed35-31de-e053-2a95a90a5554 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      15. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e90d2e3d-ec86-7d1d-e053-2995a90a9167 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      16. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2c65253d-ca49-70eb-e063-6394a90a3cd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      17. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7fcce531-bf7c-43b6-bea9-8f0602842c53 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      18. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:969cccfc-e56a-49da-9d36-47c0c3fad7f8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      19. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2278ce1b-1c19-4ad2-89c6-4530f7b78ea7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      20. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5134369d-c7f6-4569-a425-d50e5a5d694f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      21. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:344d67fa-092e-4e71-b96a-25c71bfa6bb1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      22. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:781b0d62-a760-4371-8908-1f61329928a6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      23. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d592d828-8df1-480d-b179-bb9260a9c824 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        After 150 mg intravenous administration, the mean ± SD volume of distribution is 58 ± 6 L.
      24. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3aaf3d6e-c6d5-89f5-e063-6394a90a9b77 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      25. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0f350a4b-f294-4b98-b69f-3cc789e930ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean±SD).
      26. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b88b0cbc-c883-4d17-8f46-0e5bddc57835 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      27. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:09736975-2493-4dbc-bbe0-cc56a1fec53f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      28. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5ab9c18b-9568-4dcb-90b0-252aef8f8dc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      29. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc83432-8fce-6d2a-e053-2a95a90ae73f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      30. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38119f2e-33b3-4c3c-99b7-9335d8d280d4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      31. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7a29b99-ce23-950e-e053-2995a90a1934 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      32. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9f0cceb-b24e-4526-b873-fedd877d6bc6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      33. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3e633cd0-5ee8-4a05-bcfc-0a80209bf27f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      34. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6beed8eb-446c-4575-8dc8-b798623d92c7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      35. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:55292235-bf8f-46d0-e063-6294a90a91a5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      36. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81243958-cc5a-4ec0-a64d-71682f949d5f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      37. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:360d953b-4313-45ae-b933-296547d4577d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      38. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ac0622c-440a-49a0-974f-726e6ac72a0e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      39. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:48037fc4-1aab-4ae8-aede-7c55b494877a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      40. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1006139-7dfc-4d87-a5a9-aeb380c32d24 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      41. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ddc7d92-9076-41cf-97ed-d9f9edc80298 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      42. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c585b71-5cfc-18d6-e063-6294a90a3dcf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      43. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:81774da8-cb1d-4c7d-8550-35396850d5ff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      44. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:74474aa4-4859-42d2-92d8-f23f18b34e04 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      45. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:da8438e1-755b-4195-baa7-464f3d9ee5bd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      46. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bbfdedd7-2baf-4bc6-be59-548a5cf21752 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      47. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c8dca11-78ab-45c1-8bb2-89a41ea5dfa9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      48. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a072d5d2-8c75-59cc-e053-2a95a90ac0cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      49. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ff28c5f1-da56-4072-a6fa-d689d4a6761b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      50. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:40bb60c0-a2f3-4e7f-b13c-028c906c4852 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      51. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6fc8e8b2-5d0e-4c72-9a46-6d312c3efac7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      52. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1749d731-bc8c-4374-b2a9-7c809c457f56 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      53. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b67b7865-df64-429a-9550-5333b9c713ea (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      54. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8b2f38ef-0a0c-45cc-88ca-cc086bf80641 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      55. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:39149f0e-30ed-4671-8be7-2a484f65d63b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      56. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:79cd9dea-e7d0-44db-afba-964cb99f32b6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      57. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:645824d0-eb3d-442b-806d-36a70796cb8e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      58. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e7f602a-2c5f-4651-a228-5fc5bf249205 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      59. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c859e666-d510-426b-e053-2995a90a9a3c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      60. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f781d400-7304-5d3e-e053-6294a90ac572 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      61. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:87b9171b-7d00-40fa-87ff-a717740efe8a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      62. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:23eb133e-2f74-4219-9892-0a8e770ec032 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      63. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d3fc163-25f0-2c61-e053-2991aa0a76e9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      64. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c3b232a-3e9f-4249-9e5a-295482ee288a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      65. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:707ed63a-67ca-4a62-9cbe-cdeb5c4ab506 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      66. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3cfd04ab-e421-441f-a10e-e4dd1412974d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        After 150 mg intravenous administration, the mean ± SD volume of distribution is 58 ± 6 L.
      67. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47a22de2-ec66-45be-8648-89ed3ab6e67e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      68. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1373587e-807a-462a-bff6-8a7113ce9f0a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      69. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8f982b95-4e84-4e0c-a543-747bc3dd7531 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      70. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1e28ad3d-2d34-a5d0-e063-6294a90adb9e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      71. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d22ed424-f365-44ca-8ef9-a08255a90ae8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      72. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35da078b-0da0-4757-a6c4-a9144c37e8e1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      73. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07aa1bcc-df05-44fa-92d4-63894e0e6cd6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      74. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c681c804-c6f3-d63b-e053-2995a90a6b8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      75. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9b175f8d-7667-4bfe-8bb5-fd7441eed456 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      76. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:08880902-bd44-41b6-866b-2cbad4c3f2b1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      77. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:691205ba-fa65-4bc9-ba20-7d361382cff9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      78. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:58474aa7-7c6a-3a94-e063-6394a90a870b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      79. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7652adc6-1aad-4422-b85c-0c6b11c23b73 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      80. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97e47698-97c9-4eb5-a108-5850c2aa2818 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      81. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8de89818-805a-4a20-a9b1-48cf443b6315 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      82. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c78f528f-9192-4037-bfb9-ff5718ed26c5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      83. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7538e255-95df-4991-aae0-a90d709f1e95 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      84. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4bae5032-f634-4d1e-b672-8a7e2bd6a5fa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      85. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa3ab216-372a-4a72-bfd1-88a1ffa31ba3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      86. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9c99dfa-f54d-9207-e053-2995a90ad43b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      87. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:506bf880-9564-404c-951a-703797ffdad8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      88. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c33c4d83-cc13-4104-9e24-d4cd40b17b70 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      89. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e8a30eb7-3fc5-456a-bdae-3f4095bf2c2b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      90. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07871ab8-254b-e3c2-e063-6294a90a29ab (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      91. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cdbb381-88a2-5c5a-e063-6294a90a3e1e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ± SD).
      92. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:64a65366-8577-48f2-9f8e-0332f126d3c1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      93. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7c1fd34-d615-43a2-8989-898fe11f90df (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      94. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9508cb1b-3f9f-48bd-8f34-a6fbb68c9a4a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      95. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f2ba3d6-6086-eaf2-e063-6294a90a7642 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of Gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      96. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b74a427c-9cc1-4b15-9ed2-cc891741fe67 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      97. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b26fd0c6-6aab-4957-8a32-cc7adb9b5fc9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      98. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ead7343-ab25-41b5-af4f-f903470e1dd9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      99. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c979f80b-d4b1-40f7-b878-b216db5f325d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      100. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:67330eef-c976-4862-b1ae-20f30f43df76 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      101. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:266ef369-0a56-f225-e063-6294a90a495e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      102. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ddc1342-5c83-f562-e063-6294a90a29ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      103. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ce0f0d7f-da6d-47da-a4ed-fb8f72902412 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      104. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eeb19a5a-b31d-4df8-9546-0b2b5eb5db07 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      105. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd5c9279-a1e3-2a59-e053-2a95a90a33a2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      106. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5eff7ad8-0d31-4372-82a2-ac9f549d8796 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      107. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c49d34d-bb47-406b-8f2d-b4834b2ee9d0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      108. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07f07d15-ee91-8c2a-e063-6394a90a4624 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      109. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c85ae572-9893-629e-e053-2995a90a23fc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      110. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14b1840d-a2db-4eec-bc25-029e35b042e4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      111. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:172776c0-909e-49ce-bfe1-cf154a9458ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      112. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:100ff86c-56a8-4770-9db3-b9bc6b1bd2f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      113. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56378630-e7a7-4981-8212-8ea703a433d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      114. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54c09aa5-6724-480a-a115-c88484e39e93 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      115. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9ead7825-d11b-4e00-8533-328d097b8f83 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      116. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2cb1ad6d-d389-4564-e063-6394a90a3644 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      117. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:743faa18-5e7c-4fcc-9781-4157450d90c4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      118. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afc80b8b-da39-6fb9-e053-2a95a90a2d8e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      119. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1278512b-1493-db65-e063-6394a90ab161 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      120. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d544944-ea95-42e1-8c65-9e442437f0ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      121. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b73e9db-eddb-49ba-9778-01d39ece4d16 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      122. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7a2aa696-7dac-4d03-916a-374b61a255b5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      123. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:185f264e-db32-41cd-b90d-519717b97850 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      124. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2dad630a-09d8-4f40-bdad-24e877a9ee38 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      125. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ef37f2a0-3b83-4f71-91c0-6435161b483c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      126. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:db57e37f-0a78-4c14-8768-a28bbf9fa0da (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      127. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ffe5321d-3405-46d5-a75f-c51e8f8d87b1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      128. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:330ddc5d-c67c-33dc-e054-00144ff88e88 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      129. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:137b2b9a-9d42-48d0-913f-5dc146fb689a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      130. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4470a567-93a6-a293-e063-6394a90affc1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of Gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      131. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41d1ead3-046e-4abf-ae0a-cb126a1f5848 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      132. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:912d8697-b466-48dc-88d3-d2ba90e76644 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      133. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:de990f96-96bc-406d-e053-2995a90abebb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      134. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13640281-26b4-402e-8f69-7c81cd6e0376 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      135. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d4f21e97-5e55-44c9-9b31-5f79ac2eb512 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      136. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8604417-9d43-4d27-a7ce-d4120ff201f4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      137. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f1eda6cc-d9b2-4df4-a09b-20eebded760f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      138. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:235a6954-318a-9e3a-e063-6394a90a0e21 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      139. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:021329d0-7d32-4fd8-81bf-a8b0d8b49e43 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      140. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd7adad2-e2f5-4b43-90a4-522bce0be5b3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      141. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:429a1bb5-babf-4f36-8264-46d71164f1c0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      142. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57383d2a-d2c7-bbdc-e063-6294a90ada98 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      143. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fce0c123-29d7-42bf-8c8d-8be1772e2d99 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      144. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:507bf6d0-e7a2-413d-9848-cd2445a1411d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      145. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5954a330-c225-00bd-e063-6294a90a7581 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      146. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d06380d0-c894-427e-b13e-5a8f9eb86a34 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      147. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:466273b1-c9fc-3930-c94b-aa11394d5140 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        After 150 mg intravenous administration, the mean ± SD volume of distribution is 58 ± 6 L.
      148. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:596eb696-7696-202e-e063-6394a90a2844 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      149. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6ff265b-569b-4f5c-8fdb-00b7ad4aac7c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      150. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6ecf5114-2ddc-4025-a36d-1884702dc22a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      151. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:081fd1de-acaa-4685-a053-4959d77b17e9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      152. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bff3beea-1f05-4e84-bcd2-d05782acddae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      153. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbeccab7-08aa-4da3-868f-b47a1f3d41ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      154. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2f70c496-b58c-30f5-e054-00144ff8d46c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      155. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:561f53d5-5301-42b3-b372-f3d49d642a2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      156. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:92c4d589-533b-4fe4-833f-dd68cc1f7e66 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      157. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7d77dae0-df76-4b7b-9690-713e9a60e3cd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      158. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed22b78e-93ff-4cb5-9c9c-2afe9b60dd2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      159. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7cb37f9-e1df-4e2a-bde5-9bfa0e040d7a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      160. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f38098ec-dd1a-405a-bbfb-bad62e4e7fa5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      161. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f7a943ec-9a13-45ba-9bc5-18162b86b921 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      162. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dbedccfb-0e27-4119-93b9-241c039e045a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      163. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:657349fb-41a9-4814-b4ac-4c5afbdde947 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      164. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:477691f5-0591-4544-840a-ac590e1f25a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      165. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b33c18ea-554d-3cfb-e053-2a95a90a2dd1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      166. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec1a01fe-5531-21df-e053-2a95a90a0561 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      167. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:95757436-2093-41cf-a9a9-ef2f28ac096f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      168. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:472bb279-bb4e-4246-b2a3-172483ba356b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      169. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:310ce005-5a24-489a-b23c-d42ab6a3bfed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      170. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3f2e3ac5-5233-fd57-e063-6294a90a849e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        After 150 mg intravenous administration, the mean ± SD volume of distribution is 58 ± 6 L.
      171. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:aa246838-609c-4254-a8ec-d6f463a17960 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      172. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d9d78138-e1e9-4107-9099-4910cb1422d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      173. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:618c948d-deee-44e2-98f0-e5232171dd50 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      174. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:685553b0-384e-400b-a8ae-612ceece8261 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      175. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cc1998a7-7004-4688-8b5b-525041851d1d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      176. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9e4eca9c-6a2c-4ede-a252-1a27094bf594 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      177. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bfee67dc-d2b1-4a00-92d9-a42be3189c74 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      178. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cc6615b-5447-9c0e-e063-6394a90a2883 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      179. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4cb26d6e-7963-4fe5-903e-ab5180545066 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      180. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:798575b9-ddfa-4915-9574-626abbaf025f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      181. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54ecc64b-f019-9fcb-e063-6294a90a00af (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      182. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5969871e-6c71-4c37-9d63-370718ccc80c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      183. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:df9c7c84-a8d9-4da8-babe-c55c9420d4e6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      184. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cff7de45-148b-4e96-88fd-6052bf75b5f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      185. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1af098ad-28b5-463f-8efa-24d70a77d64c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      186. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86b30e64-fe56-42b3-a0f8-d9ef5d4b8c49 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      187. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ddb3a54f-5224-4024-8804-b2a2f01d885e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      188. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97935fd9-1d4a-43b6-a5d9-de994591187b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      189. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47cd25f6-e123-9aaf-e063-6394a90aeedd (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      190. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:26aac429-a5cd-33cc-e063-6394a90aecc0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      191. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b2da7d96-73ad-4f44-8784-160a384a0961 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      192. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f396ec70-826d-45c6-a27c-343c2fac878c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      193. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:167d8b87-506c-4293-9579-563feaa71583 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      194. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca8177ed-1f0d-436e-a5ac-f58b8f7cbb25 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      195. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:772d9e7a-3811-455a-99e6-f2a3d0769b9b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      196. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed3a0d48-2e98-44ee-8743-880d1221a480 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      197. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7b404ab9-8a7e-49d4-920f-487875d14e45 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      198. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:77754734-4125-42b1-97c8-458bcab2bcf1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      199. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:45039bba-7a96-450c-95be-83a3aa4fcbd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      200. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3b4395f2-9440-4b67-97cc-5d16f3bdd05e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      201. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2ef99c3d-866a-438b-a340-8beba8d4c457 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      202. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7790d906-af26-4e60-bc6f-e906ec03cc24 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      203. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9efd0261-9fc9-4dc9-8cf3-9110157ddfc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      204. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c79d94ec-117d-4fb6-845d-1954e3472bb0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean±SD).
      205. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78088f6a-06a3-422f-b336-4a57a24adc16 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      206. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2d9bd8c-3bb9-4945-8e61-7d2703d9008c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      207. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1fd95278-842f-4bf9-abd5-4d9aa858d36d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      208. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41ce952c-6c16-4b5d-adf7-9ea114e63eb3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      209. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:30a2ed14-dcda-f972-e063-6294a90a417c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      210. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:11645bd6-7cfe-49b2-9292-2e4b0dbb84ae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      211. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5d3f27bf-3486-40fa-a4d3-5f0b2c6c0151 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      212. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eaf5e41e-8ed3-404e-84e0-392bebdbc0b7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      213. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:44f2b497-55b2-864f-e063-6294a90ad6d5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      214. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3865a6e3-112c-490c-82ac-35401336b16e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      215. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b86c81d9-9a4a-4847-be18-520e5cc5dc4b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      216. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:02304deb-7b4a-452f-9b1a-64ca0aedbcc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of Gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      217. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4aa69d04-6b32-4764-a48b-ef5313dd95d3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      218. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:75caca13-1432-4c0d-8d45-f029b0b2d417 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      219. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:180b99a5-7d3d-4ee5-a0cc-1ae0ede646ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      220. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:152adf1d-ec0c-4561-bf80-e4c7da158723 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      221. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ea83c18-7107-41f4-8305-62725c1c45c8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      222. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:397fd6d3-317b-4b61-a52b-3a09ca1d88a4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      223. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:36f74fdf-0dae-47a0-a7ea-e64ac91cd88f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      224. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6a0a75ac-e121-477b-a9d1-d11f588afc9d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      225. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:722de2a9-38b3-4518-b262-ba0d1346d0ba (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      226. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:896c7782-1137-454b-aaa6-28f42c7413ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      227. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f31172a2-0ae9-49f2-b797-b26fe33f3f64 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      228. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9d401e54-d4f5-43ba-b898-dd08fc3c7bfa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      229. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1b44a3ab-4d06-205f-e063-6294a90af368 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      230. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a95f18e-0de4-4ce1-9f97-bc2e8a5bac6a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      231. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:500ee820-0378-6fc9-e063-6394a90a109c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      232. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:632cb507-5675-2392-0460-b09c0dd14650 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      233. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25befbfa-5125-4363-8306-f862e81c0a6f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      234. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d5c9dd2c-b8ee-1406-e053-2995a90a0287 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      235. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af73fbd8-9731-e6bf-e053-2995a90af65d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      236. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b062f12c-a745-76d4-e053-2a95a90a3a1a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      237. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed219efc-84e3-5bdc-e053-2a95a90a56fc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      238. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5fbd601f-df95-4a79-a7d3-c3505e23b913 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      239. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f9bf87e4-5499-4dd7-a0c1-16025a718d14 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      240. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:88ac51c4-5fa9-4c35-9c63-f26bcb101d4b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      241. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:20e48004-d8b6-40fd-929b-b95087b4d85d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      242. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:12f0c2ee-9a44-9778-e063-6294a90a3b58 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      243. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47f2a06f-4eac-4dca-aa2a-a36dd4daaea0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      244. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:af62bb7e-162e-4e2a-8eb0-d50f66678707 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      245. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5769d849-4f27-4701-97ec-7e3ca07339d7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      246. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afa28969-91c8-83fd-e053-2a95a90a656b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      247. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:faa47fcd-2545-a946-e053-6294a90a05d2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      248. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:13b87441-8fe1-40f5-8ffb-00dcd8cc90a6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      249. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:febf610e-e088-4797-e053-6294a90a3eb5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      250. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3133fc78-dd7a-880c-e063-6394a90a89e1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      251. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ce53f62-1738-43f4-9a2e-c5dc42a91d09 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        After 150 mg intravenous administration, the mean ± SD volume of distribution is 58 ± 6 L.
      252. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3eeda97d-c3cd-65cd-e063-6394a90aae8b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      253. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e900fc4-a2b3-411f-9ab7-8dcbb97b697b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      254. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e847bcfa-f3de-404a-8a57-d8a414691e6a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      255. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2e331641-ec26-4d76-b16b-a9863c767afe (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      256. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1045db4e-4c76-4a0d-bf12-019bd96a8f59 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      257. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:999f3685-2eac-467e-bed2-1d0c36aaf0ed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      258. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17a62334-209d-4dc1-867a-e5780196a2ca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      259. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4d445d1d-02d1-4a59-b3b2-9ba5cd924c9a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      260. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1f1203f4-2184-4e13-e063-6394a90a4330 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      261. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f93eaa4f-cc1a-10ab-e053-6394a90a5ffc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      262. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2bc65375-77b8-1e50-e063-6294a90acf8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      263. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:401b30fc-e143-4906-aae1-e5b5c190d4a8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      264. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:07c8bb17-9bd4-4fab-994d-0412205b53b4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      265. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5a78ab50-993d-4857-be10-be665e02b353 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      266. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a829dc3-b2d8-4d19-a579-0597217cec9b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      267. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:934244c6-243d-436e-ad6c-f7bd28e45a86 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      268. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:583ab038-7b6e-96f8-e063-6294a90adf47 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      269. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4c22c3e6-2471-4b89-945b-f846c4d7884e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ± SD).
      270. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d35cd5ac-5ed6-2405-e053-2995a90a6946 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      271. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6670a64f-7f58-479f-b285-394abb753e2e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      272. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:dd0e12c2-1986-4ca3-a809-d703a7542419 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      273. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b286fd1-8179-d87a-e063-6294a90a2f23 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      274. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b1a9808d-31a5-4b63-afd0-d96d5a0ad7a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      275. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7ea0b220-edbb-45eb-aeb3-65283f8489a1 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      276. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:60b46f6d-efbc-487a-b672-b20df8b44cc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      277. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bec31452-b52b-4698-ba4c-0b614780ee84 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      278. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e89a7ff2-bd82-4fde-b2b7-3b9d0edf6fc8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      279. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a15d5dcc-63c4-4c06-ab91-5e22cdf234cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      280. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6702ed8f-4aaf-46fa-bf39-db75154aa44c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      281. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e286ed87-5fbc-4ff2-a05e-1f7fa658bbfc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      282. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ecb798a0-377d-4712-bb82-ec9d7116962f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      283. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:38210141-bbdc-4186-b71f-54c72f794dca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      284. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4954172-5439-48fd-8348-8a2e0d2fee62 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      285. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f6baeb5c-ca9c-4730-aeb8-8f8732e8ca3a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      286. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35004f84-90ae-45f0-a2ba-653dec507229 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      287. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b11dbff5-ceee-4a63-a093-f6efebdc2f6f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      288. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f455b415-12a2-4916-b826-246976a8af44 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      289. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ded42b88-94dd-462d-bcdf-7fd34d1e49c3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      290. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:176c5b60-93c2-4574-8b51-c15180912aaa (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      291. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c18d9d06-f796-4eb7-8fd5-1de4ebb95439 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      292. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:223a9216-6e07-49b9-8faf-bb4e529a6ae5 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      293. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ebf57adf-b066-2959-e053-2a95a90a961c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      294. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d294f6aa-ed82-90a2-e053-2995a90a2896 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      295. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:200b61d7-6e4c-923d-e063-6294a90a42cf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      296. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:86c93d8b-6286-44e2-93dd-f1b10a5d83da (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      297. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3133c863-d33b-c9d7-e063-6294a90ae898 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      298. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:25cf6c40-a239-4dd0-9cad-28da84d285db (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      299. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9c501c-24e4-da89-e053-2a95a90a64c6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      300. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8215da86-d7af-4980-b6d6-4bd46f6bfeaf (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      301. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4a975ebe-ae0a-446a-8a3d-2ca325e28f93 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      302. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3255245c-6ae6-46ab-a1c1-0b8d4d4cdaa2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      303. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:be9a572d-e98a-41c1-83c5-859d9176dd1c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      304. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b20ee34a-7f2d-4d62-a161-898565f74547 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      305. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb726cb0-d422-48dd-a8ed-adbde812b005 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      306. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:29a70e2d-d3fd-4e32-95dd-7ee721d87388 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (Mean ±SD).
      307. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2343e3a1-82d0-4c70-a086-a01a0ce81ef3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      308. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:abb56036-88df-4720-ba78-529971671545 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      309. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a75c9157-a1fc-44cc-89f8-c5a3742fb9ed (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      310. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b8b7e045-a7fe-8539-e053-2a95a90a40f8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      311. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54edd6f3-06c7-a0c7-e063-6394a90a8b4f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      312. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:72729513-bd34-44f5-9f62-297ed25c4442 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      313. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:030e656a-e384-49ac-830f-32140c18112d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      314. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:725878fa-1e2f-4fee-a9e1-a6e102c79625 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      315. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:78445dbf-c7cd-419f-a7be-72821e496628 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      316. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9a2658d5-9b0e-4921-b4c5-4c89f1630d69 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      317. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59442de1-7cf0-35f6-e063-6294a90a57d7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      318. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41844c21-9e2a-4332-a8ff-9b71ae9032b0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      319. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:16542ee6-0e0e-4d3c-8b32-60ff6ef48846 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      320. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d8daa30f-1cb3-46aa-9b68-d9aa5b0a2105 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ± SD).
      321. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9814b76c-87c6-4746-b712-3269352a901b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      322. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:63a5fc6d-ca57-4726-b70d-805ac023d959 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of Gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      323. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:efb86e22-5a84-4b33-aad0-71dd5a2c6c8f (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      324. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0919fed8-e968-b5ac-e063-6294a90afbff (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      325. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2eec52a1-9016-46dd-8b4c-8dab1d0aeece (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      326. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f651a143-3f88-49c9-b5c4-c9af55aea76a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      327. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:9c96b488-19bd-431e-af9a-b313ffd9eaae (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      328. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:37d4d465-19a5-46db-80dc-0b7334b3343a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      329. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:22f2294f-352a-4515-87c8-a6ae46e61322 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      330. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7f579665-afb7-4227-98c1-2eafee650504 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      331. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9944562-563a-423d-972c-f0313375d234 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      332. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:17988b64-723c-488d-befd-3e4e4cc44bd2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      333. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:934fefae-b895-427c-8798-4c5462b1ecc2 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      334. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8e6ed5d2-40e0-1f06-e053-2a95a90aa40e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      335. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a9f0852e-0c58-ba22-e053-2995a90adfa0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      336. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fb0b6613-57d6-4e24-946f-f5f87c460cf0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      337. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc08e35d-ef5d-1dcd-e053-2a95a90ab5de (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      338. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:afa28969-91ca-83fd-e053-2a95a90a656b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      339. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2b395a14-0f8e-7f5b-e063-6294a90ab546 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      340. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f40a4ee4-ae8e-769c-e053-2a95a90a344e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      341. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52af51ab-6543-466b-848c-13c588c98789 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      342. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:98bb408d-c402-4da6-8f9d-5de4833dedc4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      343. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc1316b6-1fc4-4990-95a8-489881772876 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      344. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0b3a4009-42f3-c84f-e063-6294a90a8068 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      345. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0e1d17d5-d39c-4144-aac0-7c0d3bc9ec0d (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      346. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3dbd447f-4791-4c62-86b4-6f7928862785 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      347. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4f95c01f-200e-bfd7-e063-6394a90abc38 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      348. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f8998c1c-c359-6f01-e053-6294a90aebf4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      349. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5385e27c-f2fa-32d5-e063-6294a90a0a8c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      350. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ba4d863d-be38-8cf5-e053-2995a90a69fb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      351. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ee9ad9ed-6d9f-4ee1-9d7f-cfad438df388 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      352. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:eb2f6784-e7be-41b6-871b-2c3c961664ab (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      353. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:8a781649-3271-47a6-995f-50f91141a48a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      354. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:cb81fd89-b32b-4538-bf5c-ab02f65b3458 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      355. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:552912b2-be59-0333-e063-6394a90a85c0 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      356. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3368bf70-d466-4765-b2b7-7fe967a8c2b7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      357. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d1aa4690-57b5-4a3e-ac12-85f777dbd05e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      358. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:915cee37-536c-4761-bdb9-b96c7ee0f956 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      359. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43a3ec78-8235-4d46-a343-2f9226745a39 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      360. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:471b2d32-0cbd-aade-e063-6394a90a1696 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      361. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:7c3ac86f-b8f7-42bf-942a-db854d946e54 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      362. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec2e07e-5a8e-41e5-9ece-485431c7c4ee (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      363. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4c7388a-19d9-4e3a-83c9-4943fb855be4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      364. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:323dad14-ded9-4432-a265-c957e46cc6db (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      365. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:35ac6b11-7b1c-47a0-a4ba-c193a0bb5b01 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      366. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6e6b9d8f-9f9e-4760-96ea-fb8b0a3bbbdb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      367. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0cd96d1-b1ef-46ec-a5a3-9505b0811b8b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      368. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2fb2233f-9152-4630-ab39-51a0cda7e5ca (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      369. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:01b810b7-f4c8-4412-bbc5-b9220d8770d8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      370. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d7646d5e-ca25-4ec5-9e4b-931edcb15a0e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      371. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1ec656c9-034f-4f14-9e6b-9779d41e1627 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      372. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:56967a93-b3c0-4043-9241-585fc64e2624 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      373. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c09c66fd-cb31-41dd-b00b-acc58bd809f7 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      374. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:97a1d45d-d5b3-4be7-9b3a-cb6f80f60291 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      375. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:481e6b68-50e4-4594-9815-32580a84ab8c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      376. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ec1c621b-db2a-1567-e053-2995a90a8695 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      377. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ed9cb5fe-7a2e-e0bc-e053-2a95a90a4470 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      378. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a1ff94a9-69c4-486a-aab2-563c7ed244c8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      379. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:0ad67a07-59d0-4aaa-906b-befbbad8af31 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      380. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:1a619a14-0b63-4cba-80e7-474c9a1c90b9 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      381. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:5969f1a8-d6d5-4967-add5-4e2492354d7b (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      382. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:765c7ce0-bbf5-4265-8ff0-1ba092c69865 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      383. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d25daaac-a8ab-4f12-acc2-4ec8fc97a2d4 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      384. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:a88edb00-2189-4c8d-9dd7-9fe1571775cc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      385. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:d0510d04-460c-47d1-be72-0ee32c4ac640 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      386. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:47214c7c-ba1b-9107-e063-6294a90a5431 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      387. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3ad96553-73a4-4a9b-8a89-10a29b794ed3 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      388. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e3429322-c442-4146-bb68-bcc3a8d01552 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      389. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:41dcc917-68d1-49f0-8223-44c21ca259ef (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      390. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:2625c0ef-5295-41de-9e81-88001a6cbecc (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      391. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:03031adf-d36b-45ec-944e-dfce5a5de91a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      392. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7674ea5-276b-4bb3-821b-4ac05c9e64e6 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      393. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9a05f0c-b5f0-422c-9d67-6d0efc921a74 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      394. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:54dc347e-cba0-ea73-e063-6294a90ab436 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58 ± 6 L (mean ± SD).
      395. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:14d61caa-17ce-4fa2-90fb-1470f3864be8 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      396. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ddcdff5-8f1f-bff3-e063-6294a90a1195 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      397. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43b67ae3-ac6f-48f5-8788-9ead08376864 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ± SD).
      398. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:32169228-e85c-4dbf-8722-cd2f8e0f5d1a (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      399. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c7f21eaa-68ee-420c-9c98-e997cc73a297 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      400. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:57492b91-1fe2-74ab-e063-6394a90a0b9e (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      401. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e877a425-2b7f-4e43-a1f9-24019cbf9685 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      402. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bc525ae4-9843-4038-a1b7-0d3543e2282c (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      403. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f0e7a6c9-ae6c-4259-81ab-a37db54e3c80 (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).
      404. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:43cbff48-8219-41ba-b67d-3ae4544b78bb (opens source in a new tab)

        Gabapentin label

        Version not recorded · Effective date not recorded

        The apparent volume of distribution of gabapentin after 150 mg intravenous administration is 58±6 L (mean ±SD).

  7. Projected row 667

    Medicine slug
    gadobenate-dimeglumine
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 1.21 ± 0.29 hours

      Numeric value
      1.21
      Unit
      hours
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:59077a3e-5f03-4342-ae24-856267545631 (opens source in a new tab)

        Gadobenate Dimeglumine label

        Version not recorded · Effective date not recorded

        The mean elimination half-life on dialysis was 1.21 ± 0.29 hours as compared with 42.4 ± 24.4 hours when off dialysis.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:f63abe56-46d9-4e32-afb1-f4e22370717d (opens source in a new tab)

        Gadobenate Dimeglumine label

        Version not recorded · Effective date not recorded

        The mean elimination half-life on dialysis was 1.21 ± 0.29 hours as compared with 42.4 ± 24.4 hours when off dialysis.

  8. Projected row 668

    Medicine slug
    gadobutrol
    Compared field
    halfLife
    Comparison state
    insufficient_context
    Reason codes
    • STRUCTURED_CONTEXT_MISSING
    Documents examined
    10
    Source count
    10
    Agreement rate
    0.5
    Recorded readings

    1. 1.8 hours

      Numeric value
      1.8
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:bd28560f-de4d-4140-874e-31df823f4dbb (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        Elimination The average elimination half-life (t 1/2 ) of gadobutrol is 1.8 hours .
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:18c67a70-0c1f-46d4-a123-66080090b71b (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        Elimination The average elimination half-life (t 1/2 ) of gadobutrol is 1.8 hours.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:3c5101a0-0c7e-4078-8dc3-a57beb9a0e92 (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        Elimination The average elimination half-life (t 1/2 ) of gadobutrol is 1.8 hours .
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4ea8ae43-22ca-40c0-be72-c91a321cafd1 (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        Elimination The average elimination half-life (t 1/2 ) of gadobutrol is 1.8 hours.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b7afe34d-b70f-41a5-b89c-561bdf29f046 (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        Elimination The average elimination half-life (t 1/2 ) of gadobutrol is 1.8 hours .

    2. 5.8 ± 2.4 hours

      Numeric value
      5.8
      Unit
      hours
      Source records
      5

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 5 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c0dd1618-0bb3-4974-846b-e5afc2311ae6 (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        After intravenous injection of 0.1 mmol gadobutrol/kg body weight, the elimination half-life was 5.8 ± 2.4 hours in mild to moderately impaired patients (80 > CLCR > 30 mL/min) and 17.6 ± 6.2 hours in severely impaired patients not on dialysis (CLCR< 30 mL/min).
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:007696d0-4b62-4937-9640-4ad619504df4 (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        After intravenous injection of 0.1 mmol gadobutrol/kg body weight, the elimination half-life was 5.8 ± 2.4 hours in mild to moderately impaired patients (80 > CL CR > 30 mL/min) and 17.6 ± 6.2 hours in severely impaired patients not on dialysis (CL CR < 30 mL/min).
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:832e0ae1-4fe1-4dff-9978-c9200bcebb55 (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        After intravenous injection of 0.1 mmol gadobutrol/kg body weight, the elimination half-life was 5.8 ± 2.4 hours in mild to moderately impaired patients (80 > CL CR >30 mL/min) and 17.6 ± 6.2 hours in severely impaired patients not on dialysis (CL CR <30 mL/min).
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:4af6ee2b-d039-497f-a8f0-bdf948e5f54e (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        After intravenous injection of 0.1 mmol gadobutrol/kg body weight, the elimination half-life was 5.8 ± 2.4 hours in mild to moderately impaired patients (80 > CL CR >30 mL/min) and 17.6 ± 6.2 hours in severely impaired patients not on dialysis (CL CR <30 mL/min).
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:52fbda34-9974-4f9f-9749-6b17d0495b62 (opens source in a new tab)

        Gadobutrol label

        Version not recorded · Effective date not recorded

        After intravenous injection of 0.1 mmol gadobutrol/kg body weight, the elimination half-life was 5.8 ± 2.4 hours in mild to moderately impaired patients (80 > CL CR >30 mL/min) and 17.6 ± 6.2 hours in severely impaired patients not on dialysis (CL CR <30 mL/min).

  9. Projected row 669

    Medicine slug
    gadopiclenol
    Compared field
    proteinBinding
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    2
    Source count
    2
    Agreement rate
    1
    Recorded readings

    1. 1.8%

      Numeric value
      1.8
      Unit
      %
      Source records
      2

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 2 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:ca582f31-1042-487f-82e4-533f1b541902 (opens source in a new tab)

        Gadopiclenol label

        Version not recorded · Effective date not recorded

        Protein binding of gadopiclenol is ≤ 1.8% at clinically relevant concentrations.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:192725e9-e83e-1a36-33f2-abee55792ab3 (opens source in a new tab)

        Gadopiclenol label

        Version not recorded · Effective date not recorded

        Protein binding of gadopiclenol is ≤ 1.8% at clinically relevant concentrations.

  10. Projected row 670

    Medicine slug
    gadoterate
    Compared field
    halfLife
    Comparison state
    agree
    Reason codes
    • COMPATIBLE_VALUES_OVERLAP
    Documents examined
    8
    Source count
    8
    Agreement rate
    1
    Recorded readings

    1. 1.4 ± 0.2 hr

      Numeric value
      1.4
      Unit
      hours
      Source records
      8

      Population and context: Unknown: population and formulation context were not structurally extracted from this source sentence.

      Show all 8 source records
      1. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:85404ca7-dbe7-4d06-b30c-4368dcd33b0b (opens source in a new tab)

        Gadoterate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics The pharmacokinetics of total gadolinium assessed up to 48 hours following an intravenously administered 0.1 mmol/kg dose of Gadoterate Meglumine Injection in healthy adult subjects demonstrated a mean elimination half-life (reported as mean ± SD) of about 1.4 ± 0.2 hr and 2.0 ± 0.7 hr in female and male subjects, respectively.
      2. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e0655aac-9508-4141-94f5-fcca6af1c41d (opens source in a new tab)

        Gadoterate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics The pharmacokinetics of total gadolinium assessed up to 48 hours following an intravenously administered 0.1 mmol/kg dose of gadoterate meglumine in healthy adult subjects demonstrated a mean elimination half-life (reported as mean ± SD) of about 1.4 ± 0.2 hr and 2.0 ± 0.7 hr in female and male subjects, respectively.
      3. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:82b83e61-6af8-4225-aa39-8cbf206f65b0 (opens source in a new tab)

        Gadoterate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics The pharmacokinetics of total gadolinium assessed up to 48 hours following an intravenously administered 0.1 mmol/kg dose of DOTAREM in healthy adult subjects demonstrated a mean elimination half-life (reported as mean ± SD) of about 1.4 ± 0.2 hr and 2.0 ± 0.7 hr in female and male subjects, respectively.
      4. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:fbebe7f2-a0c2-4fd5-b421-8fbcbaf46709 (opens source in a new tab)

        Gadoterate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics The pharmacokinetics of total gadolinium assessed up to 48 hours following an intravenously administered 0.1 mmol/kg dose of gadoterate meglumine in healthy adult subjects demonstrated a mean elimination half-life (reported as mean ± SD) of about 1.4 ± 0.2 hr and 2.0 ± 0.7 hr in female and male subjects, respectively.
      5. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:c9e273b3-481f-4899-8913-95aaddcc7662 (opens source in a new tab)

        Gadoterate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics The pharmacokinetics of total gadolinium assessed up to 48 hours following an intravenously administered 0.1 mmol/kg dose of gadoterate meglumine in healthy adult subjects demonstrated a mean elimination half-life (reported as mean ± SD) of about 1.4 ± 0.2 hours and 2.0 ± 0.7 hours in female and male subjects, respectively.
      6. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:e2c4a5ac-2df2-4cf4-a2d3-6fbe2d898ebc (opens source in a new tab)

        Gadoterate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics The pharmacokinetics of total gadolinium assessed up to 48 hours following an intravenously administered 0.1 mmol/kg dose of DOTAREM in healthy adult subjects demonstrated a mean elimination half-life (reported as mean ± SD) of about 1.4 ± 0.2 hr and 2.0 ± 0.7 hr in female and male subjects, respectively.
      7. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:6f8c9fac-c995-4bf4-950d-ab89deb291b5 (opens source in a new tab)

        Gadoterate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics The pharmacokinetics of total gadolinium assessed up to 48 hours following an intravenously administered 0.1 mmol/kg dose of gadoterate meglumine in healthy adult subjects demonstrated a mean elimination half-life (reported as mean ± SD) of about 1.4 ± 0.2 hours and 2.0 ± 0.7 hours in female and male subjects, respectively.
      8. FDA_LABELRetrieved 2026-08-30
        FDA_LABEL:b4159c07-b114-4256-b9a9-e6af811704fa (opens source in a new tab)

        Gadoterate label

        Version not recorded · Effective date not recorded

        12.3 Pharmacokinetics The pharmacokinetics of total gadolinium assessed up to 48 hours following an intravenously administered 0.1 mmol/kg dose of Gadoterate Meglumine Injection in healthy adult subjects demonstrated a mean elimination half-life (reported as mean ± SD) of about 1.4 ± 0.2 hr and 2.0 ± 0.7 hr in female and male subjects, respectively.

Access

Query or download the projection

View this filtered page as JSONDownload up to 200 filtered CSV rows
GET /api/datasets/source-consensus?limit=10&offset=660

Allowed query parameters

q
Case-insensitive text search over the public fields named for this dataset.
state
Exact comparability state.Values: agree, differ, not_comparable, insufficient_context
field
Exact recorded field key.Values: bioavailability, halfLife, proteinBinding, tMax, volumeOfDistribution
limit / offset
Pagination is required. limit is at most 200; offset is bounded. Set format=csv for the same projected page as a download.

Reuse and corrections

Keep the boundary attached

CC BY 4.0 applies to RNAWiki licenses its selection, schema, structure, and derived projection. Quoted source passages and third-party records retain their original rights.

Cite RNAWiki, this dataset identifier, and the generated date. Keep the “does not mean” statement with any downstream display so a corpus measurement is not mistaken for medical advice.

Read the correction policy